Healthcare venture capital dry powder* decreased for the first time in more than ten years. The number of digital health deals fell to its lowest point in five years.

Mega deals* accounted for 42% of 2025 funding, representing the highest share since 2021. These three indicators reveal a consistent structural pattern.

The current environment offers physician-led capital at Seed and Series A stages the most favorable entry conditions in recent years.

IN TODAY’S ARTICLE:

• Three data points marking the current healthcare VC reset

• The vintage pattern Cambridge Associates documents after every market correction

• Why concentrated capital at the top creates pricing inefficiency at the bottom

• The clinical-diligence edge that compounds when generalist capital retreats

Glossary at the bottom of today’s article.

The Middle of the Funding Stack Collapsed

By the third quarter of 2025, US digital health recorded thirty Series B* raises, compared to a three-year average of sixty-three. Series B deal volume has declined by more than half, reversing previous trends.

The Series B contraction is structural.

Series B is the stage where companies transition from product-market fit to commercial scale. It is the most costly stage to underwrite without strong clinical conviction, as valuations assume significant traction. A contraction at this level indicates that capital is no longer supporting middle-stage healthcare companies without independent validation.

Two additional data points support this interpretation. In 2025, unlabeled raises, funding rounds without a series designation, comprised 35% of digital health rounds. Mega deals, rounds exceeding $100 million, represented 42% of total funding, the highest proportion since 2021. As a result, mid-stage funding diminished while capital concentrated at the early and late stages.

Key investor takeaway: The Series A to Series B step is now the most critical decision point in healthcare venture capital. Investors deploying capital at Seed and early Series A now face less competition and more favorable entry conditions. The math for $150K-$500K check writers at Seed and Series A is notably improved.

The Series B contraction indicates where pricing will form for the next investment cycle. Physicians recognizing this trend are joining PhyCap Fund I before its closing on May 31, 2026.

The Vintage Pattern

Cambridge Associates* publishes semi-annual benchmarks for US venture capital performance by vintage year*. Recent data reveal a structural pattern: in its 2024 commentary, Cambridge reported that younger vintages (2018-22), which invested after the 2021 reset, outperformed older vintages (2015-17). The pattern continued in the first half of 2025.

The US Venture Capital Index achieved a 6.2% return in 2024, following two years of negative performance in 2022 and 2023. The recovery continued with a 6.4% return in the first half of 2025. Funds invested during the post-correction period generated the highest returns.

The underlying mechanism is clear. Capital invested during a market trough benefits from:

• Lower entry valuations than the prior peak

• Cleaner cap tables*, since tourist capital has exited

• A more constrained funding environment has restored founder discipline.

• A peer group focused on business fundamentals rather than narrative

While these conditions alone do not guarantee returns, they enable a more rigorous selection process. Funds investing under these circumstances face fewer structural challenges than those investing at market peaks.

Healthcare venture capital trailed the broader VC market. Digital health funding peaked in 2021, with the reset continuing through 2023 and 2024. The market recovered to $13.8 billion in 2025, despite a five-year low in deal count. Capital is returning selectively and in larger amounts per deal, targeting a smaller group of companies that endured the reset.

The structural conditions Cambridge Associates identifies in post-correction vintages are now evident in healthcare. Deal counts have declined, non-specialist capital has exited, and surviving companies have met higher standards. The 2024-2026 deployment window aligns with previous cycles that delivered strong performance.

The Dry Powder Paradox

Global venture capital dry powder reached $743.9 billion in December 2023, according to S&P Global Market Intelligence analysis of Preqin data. By March 2025, it had decreased by 19% to $600.9 billion, marking the first sustained decline in over a decade.

While headlines suggest that funds are actively deploying capital, the underlying structural trends are more significant.

Mega funds, which manage the largest pools of committed capital, are allocating disproportionately to late-stage and growth-stage rounds. According to Rock Health, in 2025, Series A rounds involving Andreessen Horowitz or General Catalyst averaged $24.1 million, compared to $18.9 million without their participation. This gap increases at later stages, reaching $93.6 million by Series D and beyond.

Two implications follow.

First, the largest capital pools are not competing for Seed and early Series A investments of $150K-$500K. Their focus remains on growth stages, where check sizes match their fund economics. As a result, competitive pressure on institutional investors at Seed and Series A is lower than at any point in the past decade.

Second, the premium mega-funds pay at later stages creates pricing distortions. Companies with prominent investors receive higher valuations, often based more on investor reputation than company fundamentals. Physician investors, who assess companies based on clinical workflow and adoption potential, must determine whether these premiums reflect genuine underwriting quality or simply signaling. The patterns Cambridge Associates documents in post-correction vintages indicate that this distinction is important.

Healthcare venture capital headlines rarely cover the dry powder paradox.
Instead, it appears in the deal flow PhyCap observes.
Physicians joining Fund I recognize this trend before valuations reflect it.

The Clinical-Diligence Edge Compounds in This Vintage

A third data point completes the structural analysis. In 2025, AI-enabled companies secured 54% of digital health funding and achieved an average deal size premium of 19% over non-AI-enabled peers, according to Rock Health. This premium increased to 61% at Series C.

The AI premium signals a genuine shift in healthcare technology, but it also reflects a generalist VC perspective that prioritizes AI capability over clinical adoption. These are distinct considerations.

Physicians assessing AI tools in clinical workflows use a different standard. The key question is not model performance on benchmarks, but whether the tool integrates effectively into clinical practice and physicians adopt it. Adoption drives revenue, while capability alone does not.

Investors lacking clinical expertise often overlook this distinction, yet it is the primary consideration for physician investors. In a market where generalist capital pays premiums for AI capability and withdraws from middle-stage healthcare investments, the clinical-diligence advantage becomes more pronounced. What was once a useful filter during peak periods now serves as a structural advantage in the current environment.

The mechanism is clear. When generalist investors overpay for AI capability without clinical validation, they create companies that appear well-funded but struggle with adoption. As generalists withdraw from Series B, the market reprices companies needing additional capital to achieve clinical traction. Both trends benefit investors who prioritize clinical adoption at the Seed and Series A stages.

The Structural Conclusion

Three key signals define the current environment for investors:

1) The vintage pattern that follows market corrections is reappearing in healthcare VC.

2) The dry powder paradox results in institutional capital concentrating at the top, making Seed and early Series A rounds less competitive.

3) The AI premium introduces pricing inefficiencies that clinically focused investors can leverage.

While none of these conditions guarantees returns, they collectively establish a favorable setup. The trade press seldom discusses this setup, as it does not generate headlines, but it provides a sound thesis for capital deployment based on a clear selection process.

The 2024-2026 healthcare VC vintage is developing under structural conditions that have historically led to strong performance. Physicians within the PhyCap network recognize this opportunity. The question remains whether the broader market will do the same.

The 168+ years of clinical experience across PhyCap’s network is the underwriting function that turns structural patterns into investable theses.

The companies that survive this vintage will be the ones that earned physician adoption. PhyCap Fund I closes to that network May 31, 2026.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital

GLOSSARY

Dry Powder: Capital committed to a venture or private equity fund by limited partners but not yet deployed into investments. A measure of how much investing capacity a fund has remaining.

Mega Deal: A venture capital round of $100 million or more.

Series B: The second institutional financing round, typically deployed to scale commercial operations. Companies at Series B have demonstrated product-market fit.

Series A: The first significant institutional venture financing round, typically following Seed. Companies at Series A have early commercial traction or pilot deployments.

Seed: The earliest priced round of venture financing, typically when a company has a prototype, early customer traction, or initial clinical validation.

Series C: A later-stage financing round, typically deployed to expand market share or prepare for an exit. Companies at Series C have established revenue and scaling operations.

Cambridge Associates: A global investment firm that publishes widely-cited semi-annual benchmarks tracking US and international private equity and venture capital index returns by vintage year.

Vintage Year: The year a venture or private equity fund makes its first investment. Vintage year materially affects fund returns because it determines the market conditions into which capital is initially deployed.

Cap Table: A capitalization table listing all ownership stakes in a company, including founders, employees, and investors. Cleaner cap tables indicate fewer investors with misaligned incentives or distressed positions.

SOURCES

1. Rock Health. “2025 Year-End Digital Health Funding Overview: A Tale of Two Markets.” February 2026.

2. Rock Health. “H1 2025 Market Overview: Proof in the Pudding.” July 2025.

3. Healthcare Dive citing Rock Health. “Digital Health Funding Outpacing Last Year as Huge Rounds Increase.” October 2025.

4. Cambridge Associates. “US PE/VC Benchmark Commentary: Calendar Year 2024.” November 2025.

5. Cambridge Associates. “US PE/VC Benchmark Commentary: First Half 2025.” January 2026.

6. S&P Global Market Intelligence. “Private Equity Dry Powder Recedes From All-Time Highs Amid Slow Fundraising.” December 2025. (Preqin data analysis.)

7. PitchBook. “What is Dry Powder in Private Equity and Venture Capital?” Updated May 2026.

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

Paul Tudor Jones told Patrick O’Shaughnessy that the planned IPOs in the next year are 5-6% of US market capitalization. For physicians allocating capital, this is the most important macro setup in the next twenty-four months.

The supply event will reshape where capital lands.
Healthcare sits outside the wave.

IN TODAY’S ARTICLE

• The 2026 mega-IPO* pipeline represents 5-6% of US market capitalization, the largest new-issue absorption event in twenty-five years.

• Tudor Jones’ downside framing is severe: a “breathtaking” correction, a negative 10-year forward return, and a fiscal feedback loop most coverage leaves out.

• Standard 180-day lockups* place the insider supply wave in Q1 through Q3 of 2027

• Healthcare is structurally outside the IPO pipeline, which means capital is likely to rotate into these sectors as allocations shift after the mega-IPO wave..

Glossary at the bottom of today’s article.

The Pipeline Without Precedent

SpaceX filed confidentially in April 2026. The company targets a $1.75 trillion valuation and a $75 billion raise. The June roadshow spans 21 banks with an unprecedented 30% retail allocation. That offering would more than double Saudi Aramco’s 2019 record of $29.4 billion. Anthropic targets October at a $380 billion valuation. OpenAI eyes Q4 at a $1 trillion target.

Three companies. Roughly $240 billion combined. In a single calendar year.

For context, total US IPO proceeds in 2025 were $47 billion across 216 deals. The 2026 pipeline, if executed, would run roughly five times the entire 2025 market through three names alone. PitchBook estimates these three offerings, combined, would generate more exit value than every US venture-backed IPO since 2000.

The first read frames this as an extraordinary capital formation event. The deeper read frames it as a supply event. Buyers have to absorb the new equity, and those buyers have to come from somewhere.

What Paul Tudor Jones Sees

On Patrick O’Shaughnessy’s Invest Like the Best podcast in April 2026, Tudor Jones highlighted the structural problem with one number. The planned IPOs in the next year will represent 5-6% of US market capitalization.

This is not a normal supply event. The usual IPO issuance is closer to 0.5-1% of market cap, even in active years. The 2026 pipeline is about ten times that ratio.

The mechanism is direct. Buyback capacity has supported equity prices for a decade by reducing the float*. The mega-IPO pipeline reverses that dynamic. New equity supply meets reduced buyback demand because the largest technology companies are committing enormous capital to AI infrastructure instead of share repurchases.

Tudor Jones pinpoints demand for these IPOs: Investors are reallocating funds out of existing technology stocks. In his words, that is why tech has dogged it and will continue to dog it. The Magnificent Seven’s weakness year to date is due to rotation, not earnings cycles. Investors who miss this are watching the wrong calendar.

Tudor Jones gave the bull case its due. The market has another year or two of runway and potential for another 40% upside before the cycle inverts. He is buying AI stocks for that final leg. He is also clear about what comes after.

The capital rotation out of existing tech is the trade that has already been defined for 2026, not a Q4 event waiting to happen. Allocators who recognized this early are repositioning into sectors that benefit when the cycle inverts. Pattern recognition compounds.

The Downside Picture

Tudor Jones did not soften the call. He described the eventual correction as “breathtaking” and warned that the structural setup is dangerous in ways most of the financial press underweights.

US equity valuations imply a negative 10-year forward return. In his framing, it will be “really hard to make money” in stocks over the next decade.

Market capitalization-to-GDP is above 250%, the highest in modern history. The 2000 dot-com peak was 170%. The 1929 peak was 65%. After the 2000 peak, the Nasdaq fell about 78% through the 2002 trough. The S&P 500 fell roughly 49% over the same period. The 1929 setup needs no review.

A 35% market drawdown, according to Tudor Jones, would drive capital gains tax revenue to zero. This collapse feeds into a federal budget deficit already at 6% of GDP. Such tax compression forces the Treasury to issue more debt just as the bond market absorbs forced private equity sales. The mechanics chain together.

This is the part most coverage leaves out. The IPO supply wave is the trigger. The valuation regime is the powder. The fiscal feedback loop is the amplifier.

Other respected bears have flagged correction magnitudes that would rival the worst historical drawdowns. The bears agree the correction is coming. They disagree on how violent the recovery curve looks.

The Lockup Cliff Math

Standard IPO lockups in US markets run 180 days from pricing. The math is mechanical.

SpaceX pricing in June 2026 places the lockup expiration in December 2026 or January 2027. Anthropic in October 2026 expires in April 2027. OpenAI’s Q4 2026 expiration is in Q2 2027. The cliff concentrates in the first three quarters of 2027.

At lockup expiration, insiders, employees, and pre-IPO investors can sell. Normally, lockup expirations cause volatility in the individual stock. When three large offerings unlock in six months, the volatility spreads beyond a single market.

The 2000 parallel matters. The Nasdaq peaked in March 2000. The lockup expirations from the 1999 IPO cohort ran through the first half of 2000. The timing was not a coincidence. Supply hit demand as fundamental concerns about unprofitable issuers grew.

The 2026 cohort is profitable, dominant, and concentrated in fewer names. The supply mechanics still apply.

The Venture Capital Liquidity Moment

Behind the mega-IPOs is a venture industry with the largest exit backlog in its history. PitchBook states that the combined exit value of SpaceX, OpenAI, and Anthropic exceeds that of all US venture-backed IPOs since 2000. Bain & Company estimates a broader private equity overhang at $3.2 trillion in unrealized value across 28,000 unsold portfolio companies globally.

If the 2026 pipeline executes, this becomes the largest single-year venture liquidity event in the history of the asset class.

That liquidity has to land somewhere.
This sets up the opportunity for sectors outside the immediate pipeline.

Some liquidity reinvests into the next cycle. Some returns to limited partners, who reallocate across asset classes. The flows after a major liquidity event shape the capital map for the next ten years.

This is the moment that matters for healthcare allocators. The IPOs themselves are the entry point, the first-day pops are the spectacle, and the rotation that follows is the actual capital reallocation event that requires attention.

The IPO calendar is about AI valuations.
The follow-on distribution wave determines where the next decade of healthcare capital lands. Physicians who know which verticals absorb that flow build positions before the rotation finishes.

The Healthcare Insulation

Almost none of the 2026 mega-IPO pipeline is in healthcare. The pipeline is aerospace, AI infrastructure, data infrastructure, semiconductors, and payments.

Healthcare names in the public IPO pipeline are smaller, more specific, and outside the 5-6% supply event Tudor Jones described. Clinical Care Delivery Workflow Optimization*, Software as a Medical Device*, women’s health, and specialty-focused care models are still private.

This creates a structural implication: Healthcare ventures are insulated from the supply wave expected to compress public market multiples in 2027, positioning the sector for inflows as investors seek alternatives after the IPO-driven rotation.

For a physician allocator, this is the asymmetry. You gain exposure to sectors that benefit when capital rotates out of AI concentration, without exposure to the concentration itself.

The Allocator Lens

A measured capital allocator does not need to time the peak. The allocator needs to understand the rotation.

Healthcare ventures in clinical workflows, regulated medical devices, and underserved specialty verticals do not need an AI thesis to succeed. They require clinical judgment on which solutions will actually be adopted in practice environments.

The 2027 cascade, if it arrives, does not break healthcare. After major liquidity events, history shows capital reallocates to sectors outside the supply wave.

Allocators who position before the redirection arrive early.
Those who wait for the cascade act after pricing adjusts.
The window between the two is short.

WORK WITH PHYCAP FUND

We are closing Fund 1 May 31, 2026.
Reach out and work with us.
The investments are exciting and we are making a difference.

Physicians Capital Fund invests $150K-$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital
LinkedIn: linkedin.com/company/phycap
X: x.com/physicianscap

GLOSSARY

Lockup Period: A contractual restriction preventing insiders, employees, and pre-IPO investors from selling shares for a defined period after an IPO, typically 180 days. Designed to provide post-listing price stability.

Mega-IPO: An initial public offering with a valuation exceeding $100 billion. A category that effectively did not exist before the late 2010s.

Float: The portion of a company’s shares available for public trading, expressed as a percentage of total shares outstanding. Lower floats reduce initial trading liquidity.

Roadshow: The marketing process between IPO filing and pricing where company management and underwriters present to institutional investors to build the order book.

Clinical Care Delivery Workflow Optimization: Technology and service categories that improve the operational mechanics of how clinical care is delivered, including documentation, coordination, and throughput.

Software as a Medical Device (SaMD): Software intended to perform one or more medical functions without being part of a hardware medical device. Subject to FDA regulation.

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

SOURCES

1. Paul Tudor Jones, interview with Patrick O’Shaughnessy, Invest Like the Best, Episode 469 (”Lessons From 50 Years in Markets”), published April 28, 2026. Recorded mid-February 2026. Source for the 5-6% of market cap framing, “breathtaking” correction language, “really hard to make money” framing, capital gains tax revenue cascade, and the negative 10-year forward return implication.

2. Tudor Jones, CNBC Squawk Box interview, May 7, 2026.

3. SpaceX confidential S-1 filing (”Project Apex”), April 2026; reported across Fortune, Bloomberg, and equity capital markets coverage.

4. PitchBook analyst note, “The mega IPOs that could shut out the rest of VC,” March 19, 2026.

5. Bain & Company Global Private Equity Report, 2025.

6. EY Global IPO Trends, 2025 Annual Report.

7. Renaissance Capital IPO Pipeline Tracker, Q1 2026.

8. Neuberger Berman Disruptive Forces podcast: “2026: A Mega-Cap IPO Odyssey,” April 2026.

9. Wall Street Journal and Barron’s coverage of Tudor Jones’ market cap to GDP framing, May 2026.

10. Historical Nasdaq and S&P 500 peak-to-trough data, 2000-2002 cycle, via Yardeni Research and standard historical price series.

PhyCap reviews every pre-seed pitch through the same five-step structure, applied in order. Founders should use this as a self-audit before sending. Physicians can view it as insight into how capital is filtered before reaching cap tables.

IN TODAY’S ARTICLE:

• The sequential structure of a pre-seed healthcare diligence review

• How a clinical premise becomes the gate that determines what else gets evaluated

• The reimbursement and regulatory questions that produce a path versus a thesis

• The phenotype of the physician founder that consistently clears all five filters

Glossary at the bottom of today’s article.

Why the Sequence Exists

A pre-seed* fund of our size sees more decks than any partnership can deeply diligence. The math is unforgiving. The function of a framework is to triage with discipline, then discover with rigor. Discovery happens after the deck clears the filters.

Most decks fail early in the process; this reflects fit, not founder quality.

The five filters are sequential: a weakness at any layer ends the conversation, applying the same logic clinicians use for diagnosis.

Filter One: Clinical Premise

The first question is whether the problem the company is solving is a real clinical problem.

This sounds obvious. It is not. A meaningful share of healthcare decks describe a problem that exists in the abstract but does not exist on a Tuesday afternoon in a busy clinic. The problem is real on a slide. It is invisible at the point of care.

Clinical premise* clears the filter when the founder can answer four questions in the founder’s own words:

1. Who is the affected physician or care team, by specialty and setting?

2. What does the existing workflow look like before the product is introduced?

3. What is the workflow for the product?

4. What clinical outcome or operational metric improves, and by how much?

If the founder cannot answer these without reaching for a deck slide, the premise is not yet clinical. It is a hypothesis dressed in clinical language.

The strongest decks in this category are built with at least one physician who practices in the affected specialty. Not as an advisor. As a working voice in product decisions. The difference is observable in two minutes of conversation.

PhyCapFund.com

Most decks fail the clinical premise test on the first read. A physician who practices in the affected specialty sees the gap in seconds. The capital allocators who read this newsletter train themselves to read decks the same way.

Filter Two: Workflow Integration

A product can solve a real clinical problem and still fail because the workflow* required to use it is incompatible with the day the physician actually has.

Many clinically sound pre-seed companies stall at workflow integration: the product is good, the workflow is not.

We look for three signals.

First, the product must reduce clicks, steps, or cognitive load. If it adds a step, even a small one, the adoption curve will be flat. Physicians do not have spare attention to allocate to a tool that performs a task the EHR already performs adequately.

Second, the product must integrate with existing infrastructure. If the founder has not stress-tested the integration story with a working clinician inside a real system, the integration story is theoretical. Theoretical integration is the most expensive line item on a startup’s burn rate*.

Third, the product must respect the time signature of clinical work. A tool that requires 15 minutes of physician input to deliver value will lose to one that requires 40 seconds, even when the longer tool is better in isolation.

Founders who clear this filter typically have logged shadowing hours, not just interview hours. The difference shows up in the deck.

Filter Three: Reimbursement Clarity

Most pre-seed healthcare founders have a reimbursement thesis.

Some have a strategy; a few have a path. We look for the path.

A path means the founder can name the specific payer, the specific code or contract type, and the specific clinical or operational evidence required to unlock payment. If the answer is “we will figure that out post-Series A,” the answer is not yet a path.

There are healthy exceptions.

A pure Software as a Medical Device* (SaMD) play with FDA clearance and a procedural CPT* pathway has a different reimbursement profile than a workflow tool sold direct to a health system. A Women’s Health diagnostic targeting employer benefits has a different sequence than a chronic care platform billing CMS.

The filter is not “show me a billable code today.”
The filter is “show me you understand the sequence and the unlock.”

Founders who clear this filter usually have a payer or health system advisor with operating experience inside a benefits or contracting function. Not a board name. A working relationship.

PhyCapFund.com

Clarity about reimbursement is where most decks stop being abstract.
The path requires named payers, named codes, and named clinical evidence.
The PhyCap network compresses 168+ years of clinical experience into the moment a deck is opened.

Filter Four: Regulatory Pathway

Regulatory clarity is structured in some categories and ambiguous in others. The filter at pre-seed is whether the founder has correctly identified where they are.

For SaMD and certain diagnostic categories, the FDA pathway is well-defined. The founder needs to know whether the product is exempt, 510(k), De Novo, or PMA. They need a regulatory advisor with relevant experience. They need a realistic timeline. They need to understand what the predicate device strategy looks like, or why one does not exist.

For workflow software not classified as a medical device, the regulatory question shifts to data privacy, security, and any state-specific clinical practice considerations. HIPAA compliance is table stakes, not a differentiator.

For Women’s Health products, the regulatory landscape is broader. Some products are device-classified. Some are clinical service models. Some are direct-to-consumer with FTC implications. The founder needs to know which one they are operating in.

The filter clears when the founder can articulate the pathway in two sentences, name the relevant precedents, and price the regulatory cost into the financial plan with credible inputs.

The filter does not clear when the regulatory plan is “we will hire a consultant once we close the round.”

Filter Five: Team Composition

The last filter is the one most often misread. Team composition is not about pedigree.

We look for three things.

The team needs operating experience in the specific domain it sells into. For example, a perioperative tool requires experience in the perioperative setting.

Adjacent experience is not enough.

Second, the team needs a strategic physician phenotype who executes—not a Key Opinion Leader, but a clinical co-founder who writes KPI reports, joins standups, drives feature scope, and represents the product in language clinicians use.

Third, the team needs commercial honesty: specifics like named customers and realistic conversion estimates, not generalities and adjectives.

PhyCapFund.com

The strategic physician phenotype is rare on the founder side.
It is equally rare on the investor side.
The physicians who read this newsletter are the ones building portfolios from the second.

The Decision Layer

The five filters are necessary.
They are not sufficient.

After the filters clear, the decision becomes a question of timing, fund construction fit, and whether PhyCap’s network adds value that the founder cannot get from a generalist healthcare VC.

Not every strong company is a fit for every fund, and the inverse is also true.
We pass on companies we admire.
We engage with companies where we believe we can be additive, drawing on 168+ years of combined clinical experience across 13+ specialties.

Founders who view the filters as a checklist may build polished decks and still get passed. Those who use the filters diagnostically rebuild what is missing and run better companies.

The shortest path to a first call with PhyCap is to make sure the deck answers the five filters in the founder’s own words, in the order presented above, with the rigor a working physician would expect.

The publication itself is the filter.

The founders who self-select into the framework before sending are the ones we want to talk to.

WORK WITH PHYCAP FUND

We are closing Fund 1 May 31, 2026.
Reach out and work with us.
The investments are exciting and we are making a difference.

Physicians Capital Fund invests $150K-$500K in Pre-Seed and Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital
LinkedIn: linkedin.com/company/phycap
X: x.com/physicianscap

GLOSSARY

Pre-Seed: The earliest institutional funding stage, typically before product-market fit is established. Check sizes vary, but the round usually funds the work required to reach a Seed round.

Clinical Premise: A PhyCap term for the underlying clinical reality a startup claims to address. A clinical premise clears when the founder can describe the affected specialty, the existing workflow, the changed workflow, and the clinical or operational metric that improves.

Workflow: The sequence of steps a clinician or care team performs to complete a clinical or administrative task. Workflow integration measures how well a new product fits into that sequence without adding friction.

Burn Rate: The rate at which a startup spends capital, typically expressed monthly. Burn rate determines runway.

Reimbursement: The mechanism by which a healthcare product or service is paid for, typically by a payer, employer, government program, or direct customer. The reimbursement path is the specific sequence required to unlock payment.

Software as a Medical Device (SaMD): Software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device. SaMD is regulated by the FDA and other global regulators.

CPT (Current Procedural Terminology): The code set developed and maintained by the American Medical Association used to report medical, surgical, and diagnostic procedures and services among physicians, payers, and regulators.

510(k): An FDA premarket notification submission used to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

De Novo: An FDA pathway for novel devices of low to moderate risk that lack a predicate device for 510(k) clearance.

Key Opinion Leader (KOL): A clinician with influence in a specialty, typically engaged for pharmaceutical and medical device commercial strategy. A strategic physician phenotype is distinct from a KOL.

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

SOURCES

1. U.S. Food and Drug Administration. “Software as a Medical Device (SaMD).” FDA Center for Devices and Radiological Health. https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd

2. U.S. Food and Drug Administration. “Premarket Notification 510(k).” FDA Center for Devices and Radiological Health. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k

3. U.S. Food and Drug Administration. “Evaluation of Automatic Class III Designation (De Novo) Summaries.” FDA Center for Devices and Radiological Health. https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries

4. American Medical Association. “CPT Code Set Overview.” https://www.ama-assn.org/practice-management/cpt/cpt-code-set-overview

Retirement savers now access an asset class once reserved for endowments and sovereigns.
Median GP edge erodes.
Edge-bearing GPs compound.
The picker problem gets harder, not easier.
The math defines the asset class.

About $9 trillion of US defined-contribution (DC) retirement capital, money saved by individuals in retirement accounts such as 401(k) plans and IRAs, has been effectively walled off from private markets, including private equity and venture capital, for 40 years.

The August 7, 2025, executive order directed the Department of Labor (DOL) and the Securities and Exchange Commission (SEC) to revise their interpretive guidance.

This order has begun unwinding that wall. The consequences for venture capital allocation are not what the headlines indicate. We call this the capital-funnel inversion.

The funnel that once sent institutional limited partners (LPs), such as pension funds and endowments, to a small set of general partners (GPs), the firms that manage these investments, now widens at the top and narrows at the bottom.

The picker problem, which PhyCap has discussed, meaning the challenge of selecting the right venture capital managers, applies even more when retail capital (individual investor funds) is the marginal entrant.

The Condition

The wall around defined-contribution capital was not built by statute. It was built by interpretation. The Employee Retirement Income Security Act of 1974 imposed a fiduciary duty, meaning plan administrators were legally obligated to act in the best interest of plan participants.

Over the past four decades, court decisions (case law) and Department of Labor guidance have reinforced these obligations. The effect was a de facto, or unofficial, exclusion of illiquid alternatives, investments that cannot be quickly sold or exchanged for cash without loss in value, from 401(k) menus. Plan sponsors weighed the risk of being sued (litigation exposure) against the benefits of adding private investment funds and chose to omit them.

The post-2008 trend of indexing, or investing in index funds that mirror market benchmarks, reinforced this omission. Vanguard, BlackRock, and State Street built default lineups with daily-priced (valued at the end of each trading day), low-fee index products. Anything not priced at 4 p.m. each trading day became structurally inadmissible, or not allowed by default.

The result is a $9 trillion pool focused on public equity beta. A long tail of target-date funds buys the same beta in different age-based amounts. For the median physician participant, this means decent returns during a 15-year bull cycle but almost no exposure to the top-performing asset classes in the same period.

The supply side moved in the opposite direction. Institutional fundraising in private markets has dropped for several years. Endowments rebalanced after drawdowns from the denominator effect in 2022 and 2023. Public pensions cut alternative allocations due to fee scrutiny.

Sovereign wealth funds shifted toward direct deals and away from blind-pool commitments. The pot, as Dan Primack at Axios said on August 7, 2025, has been emptying. He called the executive order a “major realignment of the capital markets.” Private equity becomes “more ubiquitous,” and “adding 401(k)s could refill the pot after several years of fundraising declines.”

PitchBook’s Madeline Shi, writing the same day, framed the demand side: the order could “clear the way for 401(k) investors to access alternative assets for better returns and diversification.” The 180-day agency evaluation window was established and closed on or around February 3, 2026, three months ago. The interpretive guidance is now under active revision, and the structural condition has already moved. Plan recordkeepers, target-date sponsors, and large registered investment advisers are building products around an opening that, for practical purposes, is already taking shape.

The Thesis

The capital-funnel inversion occurs when these two flows collide. For context, a median venture fund returns about as much as its public-market equivalent, meaning the typical net return after fees over ten years is similar to that of publicly traded assets like stocks or bonds.

Dispersion, the range of outcomes, is wide. Top-quartile vintages (the best-performing funds from a particular investment year) exceed 20% net IRR (internal rate of return, or the average annual return after fees); bottom-quartile vintages return only a fraction of the invested capital. Dispersion is the asset class: it defines the difference between the best and worst outcomes.

When capital is scarce, institutional LPs (limited partners, such as pensions or endowments, who invest in funds) rigorously police dispersion. Their due diligence costs are amortized across very large checks, making deep scrutiny cost-effective. When capital is abundant, and marginal entrants like 401(k) recordkeepers (firms that manage retirement plans) package target-date sleeves (investment products designed to mature at a particular future date), dispersion doesn’t narrow; it widens.

Fee pressure further compresses the profitability for generalist funds. Indexed-style private-market products are structured to mimic equity beta (general stock market returns) with a liquidity overlay (some ability to access cash), which dilutes the distribution of median returns. The capital-funnel inversion describes both effects: more dollars flow at the top of the funnel, but only a smaller set of GPs (general partners, or fund managers) with genuine structural advantages survive at the bottom.

This is where the picker problem matters.

Retail capital is, by design, the least informed allocator at the table. It won’t do the diligence required to distinguish a generalist GP (a private equity firm that invests across multiple sectors) from a specialist GP (a firm focused solely on healthcare). It will buy what its recordkeeper (the firm administering the retirement plan) offers.

The recordkeeper, in turn, will select GPs with the largest brands and the lowest fees. That is the group whose edge is most exposed to dilution. The result: the median dollar of new 401(k) capital underperforms its public-market equivalent. But the top-quartile dollar compounds harder than before.

PhyCap’s picker-incubator-distributor model, outlined in the research paper, is designed for the second half of that distribution. The fund’s edge is not informational. An informational edge, a faster read on a deal, a better network of bankers, a sharper financial model, erodes when capital floods in. PhyCap’s edge is structural.

The picker is also the end-user and the distribution channel. With 168-plus combined years of clinical experience across orthopedics, spine surgery, OB/GYN, emergency medicine, and radiology, the GP team identifies adoption barriers (EHR friction, documentation overhead, workflow integration failure) before capital is deployed. Member practices function as the pilot network. Portfolio companies bypass the hospital procurement cycle and reach physicians directly. Each of these is a structural property of the fund.

None of them erodes when a recordkeeper writes a check.

The Counterargument

The main objection a careful physician LP (limited partner—an institutional investor in investment funds) could raise is the one Simon Tang of Accelex stated in early reporting. “Private markets are a different ballgame.

Retail investors are used to instant pricing, clean data, and daily performance updates.” The counterargument isn’t that retail capital can’t earn the return. It is that a 401(k) menu (with daily NAV, net asset value, daily redemption, and daily reporting) does not match a private fund, which prices quarterly, gates redemptions (restricts redemptions), and reports on delays.

The mismatch is not cosmetic. It is the main source of fiduciary litigation risk that plan sponsors have weighed for 40 years.

Shana Orczyk Sissel, CEO of Banrion Capital, was blunt in the same news cycle: “I will preach the gospel of alts [alternative investments, such as private equity or private credit]... but not everything’s meant for every person.” The structural answer is to take her point seriously.

The capital-funnel inversion does not mean every 401(k) participant must own private credit (loans to companies that aren’t traded publicly), late-stage growth equity (investments in mature private companies), or seed-stage venture (early investments in startups). It means a significant slice of the $9 trillion pool will enter private markets.

Recordkeepers (firms tracking retirement plan assets), target-date sponsors (managers of funds tied to a retirement year), and fiduciary-grade products (investment products designed to meet legal standards for prudent management) will manage the liquidity mismatch in defensible structures for plan administrators.

For a physician LP, the real implications differ from the headlines.

The pricing and data mismatch Tang described is not a reason to wait for retail products. It is a reason to see that retail products will flow to GPs whose returns fit daily-NAV wrappers. Those are not the GPs whose edge compounds in a capital-funnel inversion.

The Allocation Implication

The facts lead upstream. The general partners (GPs) whose unique advantage holds when individual (retail) capital enters are those whose advantage was never based on privileged information. Physician-led healthcare venture capital is one such model.

Here, the picker (decision-maker) is the end-user (physician), and the distribution channel (how investments are made available) is the cap table (record of partners and their ownership). Diligence, the process of evaluating opportunities, happens in the clinic (where decisions are implemented), not in a data room (a centralized document repository).

Self-directed Individual Retirement Accounts (IRAs) and donor-advised funds are the routes through which physician limited partners (LPs) invest today. The larger 401(k) opening will depend on the agencies’ final steps. Either way, the capital-funnel inversion (shift in capital flows) will unfold.

For a physician with $500K to $5M to invest, the question is not whether private markets become more accessible, but which side of the inversion their allocation lands on.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K–$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com |
Email: info@46.capital |
Socials: LinkedIn X

Glossary

Defined-Contribution (DC) Capital. Retirement assets held in 401(k), 403(b), and similar employer-sponsored plans where contributions are defined but benefits depend on investment performance. Approximately $9 trillion in aggregate.

ERISA Fiduciary Duty. The standard of care plan administrators owe under the Employee Retirement Income Security Act of 1974. The interpretive scope of this duty, not the statute itself, is what historically excluded illiquid alternatives from plan menus.

Capital-Funnel Inversion. PhyCap’s framing for what happens when a previously-restricted capital pool (DC retirement assets) opens into a previously supply-constrained asset class (private markets). The top of the funnel widens, the bottom does not. Dispersion grows.

Public-Market Equivalent (PME). A benchmarking method that measures private fund returns against what the same cash flows would have earned in a comparable public index. Median venture funds approximate their PME net of fees over a ten-year horizon.

Net Internal Rate of Return (Net IRR). The annualized return to limited partners after management fees and carried interest. Top-quartile venture vintages exceed roughly 20 percent net IRR over a ten-year horizon.

Dispersion. The spread between top-quartile and bottom-quartile fund returns within a given vintage. In venture, dispersion is the asset class.

Denominator Effect. The 2022–2023 phenomenon in which public-market drawdowns inflated private allocations as a percentage of total portfolio, prompting institutional LPs to trim private commitments.

Daily Net Asset Value (Daily NAV). The pricing cadence public funds use to mark holdings each trading day. Plan menus structurally exclude assets that cannot be priced daily, which has historically excluded private funds.

Picker Problem. The challenge of selecting GPs whose edge is durable. Retail capital, by construction, is the least-informed allocator and concentrates in GPs with the largest brand surface, not the strongest structural edge.

Recordkeeper. The intermediary that administers 401(k) plan operations. Recordkeepers will be the primary distribution channel for private-market access in DC plans.

Target-Date Fund (TDF). A diversified product that automatically rebalances toward fixed income as a participant approaches retirement. TDFs hold the majority of default DC contributions and will be the first vehicle to receive private-market sleeves.

Self-Directed IRA. An individual retirement account structure that permits private fund investments. An existing pre-rule access route for physician LPs allocating today.

Donor-Advised Fund (DAF). A charitable giving vehicle that can hold private fund interests with tax-advantaged treatment. An existing pre-rule access route.

Generalist vs. Specialist GP. A generalist GP allocates across sectors and competes on informational edge. A specialist GP allocates within a domain and competes on structural edge: network, distribution, end-user proximity.

Structural Edge. An edge that does not erode when capital floods in. Examples: the picker is the end-user; member practices function as the pilot network; portfolio companies bypass hospital procurement.

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

The dividing line is the patient encounter.

In front: clinical AI, diagnostics, imaging interpretation, ambient documentation, drug discovery. Behind: business-stack AI, revenue cycle management, prior authorization, denials management, coding, contracting, scheduling, and eligibility.

The first captures workflow defensibility; the second, reimbursement defensibility. These are distinct underwriting problems.

The gap between how generalists and physician-led capital price them is the allocation opportunity.

The Two Markets

The US digital health sector drew $14.8 billion in venture funding in 2023.

That capital flowed into a category most fund managers describe as “healthcare AI,” without distinguishing between the patient-facing layer, which interacts directly with patients, and the revenue layer, which integrates with financial or billing systems.

The conflation is not surprising; both categories involve models trained on medical data, both sit inside healthcare systems, and both generate compelling pitch narratives about cost reduction and efficiency. But the underwriting discipline required for each is fundamentally different.

Clinical AI, Heidi, Abridge, Suki, and Ambience, compete on workflow integration and physician adoption. The real defensibility question: Does the model survive a clinical shift? The data is telling: clinical decision-support AI fails 70% of the time, mostly due to cognitive overload and irrelevance.

AI for hospital operations fails 50–60%, typically for similar reasons from the administrative side. These are adoption failures, not technology failures. Generalist VCs lacking clinical workflow insight cannot underwrite adoption risk from first principles, they rely on standard metrics like ARR, acquisition cost, and hospital logos, not on real-world usage during a high-volume shift.

Business-stack AI fails differently. Companies building reimbursement-native AI models trained to read payer policy, route authorizations, identify denials, and optimize coding compete on rules-based accuracy.

The buyer is the CFO or revenue cycle director.
ROI is measured in recovered revenue and reduced admin overhead.
The regulatory surface is payer contracts and CMS rules, not FDA pathways. Primary risk is rule-change obsolescence, not adoption friction.

This is the structural condition that generalist capital has not priced: reimbursement-native AI carries a model-decay risk that the prior generation of RCM SaaS, Athena health, Waystar, and the mature billing infrastructure stack, never faced. Rule-based SaaS processes reimbursement rules.

AI trained on reimbursement rules becomes the rules. When the rules change, the model degrades. The prior SaaS generation issued a software update. The AI generation retrains a model, rebuilds the data infrastructure, and continuously monitors the rule-change stack. That is a different cost structure, a different defensibility equation, and a different underwriting problem.

The Thesis: Reimbursement-Native AI and the Picker Bottleneck

Project Stargate’s $500B private-sector AI infrastructure buildout is the catalyst. As compute costs fall and foundation model capabilities rise, startups in both clinical and business-stack AI will proliferate faster than allocators with relevant domain knowledge can evaluate them. The picker bottleneck, the gap between available capital and capital capable of precise underwriting, is growing on both sides of the patient-encounter line. However, the gap widens more on the business-stack side, where required underwriting knowledge is even more specialized.

A generalist VC can hire a physician consultant to evaluate clinical-AI workflow fit. The clinical question “Does this tool survive the shift?” is an observable phenomenon. The reimbursement question-”Will this model remain accurate across the next rule cycle?” requires a reader who understands the mechanics of payer contracting, the IDR process, CMS rulemaking timelines, and the behavioral economics of denial management. That is not consultable; it is embedded.

The January 2026 closing of the B1/B2 supplemental-payment loophole is the canonical recent example. States had been using the B1/B2 statistical methodology to obtain supplemental federal Medicaid payments. The loophole closed in January 2026, leaving startups that had embedded supplemental-payment mechanics into their revenue models in immediate fiscal distress.

A generalist fund could not have underwritten that risk 18 months out because it lacked the regulatory reading capability to flag the loophole, track CMS commentary, or model the exposure.

A physician-led fund with active engagement in healthcare policy, as PhyCap maintains through its Physician-Led Healthcare for America partnership and Fred Liss, MD’s policy work at CMS and HHS, occupies a different information position.

The Picker-Incubator-Distributor framework, applied specifically to business-stack AI, maps the PhyCap structural advantage. At the picker layer: 168+ years of combined GP (General Partner) clinical experience, including the reimbursement mechanics that generalist capital cannot access.

At the incubator layer: member physician practices as first-customer networks, where a reimbursement-native AI tool’s accuracy can be tested against real payer adjudication before follow-on capital is deployed.

At the distributor layer: a physician LP (limited partner) base that is simultaneously the end-user, the validator, and the customer, collapsing the Hospital CFO (Chief Financial Officer) Death March into a direct-to-physician distribution path.

For clinical AI, the model captures workflow defensibility: does the tool integrate into the shift? For reimbursement-native AI, the model captures reimbursement defensibility: does the tool remain accurate as the rules evolve?

That second question is the harder underwriting problem.

It is also the one where physician-led capital has the steepest structural advantage, because the knowledge required to answer it is not separable from the experience of operating within the reimbursement system.

The Counterargument

The strongest objection from a skeptical physician, LP, is that this is just RCM SaaS in a new outfit: Athena health built a durable business on reimbursement automation, and Waystar went public. The category is not underpriced, it is mature, competitive, and well-understood.

The response is the rule-change risk premium. Athena health and Waystar were built on a relatively stable rule environment; their defensibility came from data network effects and switching costs.

For example, a physician’s office that has processed ten years of claims through Athena’s clearinghouse is unlikely to move; that is a genuine moat. In contrast, the native AI for reimbursement is building something structurally different: models that not only automate rule application, but also learn the patterns within the rules.

This shift creates a new vulnerability, model decay from rule changes, that the prior generation did not face, nor is it one that mature RCM SaaS pricing reflects.

The 46VC partnership addresses the institutional discipline gap. PhyCap’s clinical expertise identifies the reimbursement-reading edge, while 46VC validates business model, unit economics, and venture structure.

The claim that physician investors are “too close” protects manager fees more than it reflects an investment flaw. Clinical expertise identifies utility; 46VC validates the business. This combination meets the unique needs of reimbursement-native AI, beyond the reach of generalist capital. The Allocation Implication

A physician LP evaluating healthcare-AI exposure in 2026 is looking at two markets that the fund data does not separate. Clinical AI is well-priced and crowded. The Heidi and Abridge territory is visible to every healthcare-focused VC on both coasts, the adoption narrative is legible, and the failure rates are already priced into the higher-risk premium generalist funds that accept for seed-stage clinical-AI positions.

Business-stack AI, and reimbursement-native AI in particular, is priced without factoring in rule-change risk. Generalist capital prices it as mature RCM SaaS with a model layer. And model-decay risk is structural and grows as models get more capable and embedded. Physician-led capital’s underwriting advantage here is categorical. The picker bottleneck is widening under new infrastructure, so the window to capture this advantage is limited.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K–$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com | Email: info@46.capital | Socials: LinkedIn X

DISCLOSURE
This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

The hospital pilot isn’t a de-risking event.

It’s the thing that kills the company.

Every digital health collapse of the last five years ran the same sales cycle.

The single most expensive line item in early-stage healthcare go-to-market is the Hospital CFO Death March, the 12-to-24-month procurement and approval cycle an early-stage company must navigate to convert a pilot into committed enterprise revenue.

It is the specific failure mechanism that killed a generation of well-funded digital health companies. For founders selling into physicians in 2026, it is also the mechanism that physician-anchored capital is structurally designed to collapse.

Pilot contracts with major hospital systems have historically been the de-risking event that seed-stage healthcare companies were supposed to reach. In practice, the pilot has been a vanity metric, converting to enterprise spend in the single digits to low teens.

The structural reason is not pilot quality.
It is the counterparty.

A counterparty whose own balance sheet is downgraded to junk mid-cycle, as Moody’s did with OU Health after the 2025 state intervention, is not a counterparty underwriting a durable Series B. The go-to-market through that counterparty is the death march, and the runway cost of running it is what kills the company.

The Architecture

The hospital CFO’s sales cycle is not a decision made by a buyer. It is a decision made by a committee stack.

The stack usually runs six to ten committees deep: the department chair’s clinical review; the CIO’s technology-integration committee; the CMIO’s clinical informatics review; the Chief Nursing Officer’s workflow-impact review; the compliance and privacy officer; the revenue-cycle committee; the vendor-risk committee; the finance committee; the CFO; and, at academic systems, a separate research-integration layer. Each committee has its own quarterly cadence. Each has its own veto. None of them is paid to say yes quickly. For a seed-stage company burning $400K to $700K per month, running that stack to an executed enterprise contract consumes 12 to 24 months of runway.

The counterparty credit is the second structural problem. Nonprofit hospital systems operating at thin margins use pilot budgets as discretionary line items. The first expense cut is when quarterly operating performance slips. When the counterparty also has stressed credit, which a growing share of nonprofit systems now do, as the OU Health downgrade made explicit, the pilot-to-enterprise conversion decision is governed by the system’s bond covenant math, not the tool’s clinical value. A clinically successful pilot in a stressed system often does not convert because the system cannot underwrite the enterprise spend, regardless of the pilot outcome.

The observed result is the segment-level failure data. Telemedicine platforms that implemented the 2020 hospital-pilot playbook failed at 30 to 40 percent. AI clinical decision support failed at 30 percent. Point-of-care diagnostics failed at 40-50%. The cause was not founder execution. It was the committee stack multiplied by the counterparty credit layer. Every named digital health collapse of the last five years, Olive AI, Pear Therapeutics, Babylon Health, Forward, ran a version of the same death march, and ran out of runway before enterprise conversion did.

The Response

Physician-anchored capital collapses the death march by replacing the committee stack with a cap-table-aligned adoption base.

The collapse mechanism has a specific architecture. The fund’s LP base comprises practicing physician-owners. The owners are, by construction, the buyers and the users. A tool that clears the clinical-diligence bar at the picker stage is offered to the LP network at launch, installed inside the owner’s practice within weeks, and generates usage data across a geographically and specialty-diverse sample. The cycle that used to take 18 months in a hospital procurement committee takes 2 to 8 weeks in a physician-owner practice, because the decision-maker is the user and the payer.

The unit economics are what institutional allocators need to model.

Sales cycle compression. Replace a 12-to-24-month hospital cycle with a 2-to-8-week physician-owner cycle. The ratio is roughly an order of magnitude at the seed stage, which is where the company either survives or does not.

Conversion rates. Hospital pilot conversion to enterprise runs in the single digits to low teens. Physician-owner adoption, when the clinical bar is cleared, converts into paid usage at materially higher rates. The structural reason is not sales effort; the reason is that the user and the decision-maker are the same person.

CAC. Customer acquisition cost for a tool distributed through a physician-LP cap table is a fraction of the CAC for the same tool distributed through hospital procurement. The differential is applied to the runway extension.

The PhyCap portfolio runs the mechanism in three different shapes of healthcare technology, and the compression holds across all three.

BioReact is an AI-powered bioprocess optimization platform headquartered in Indianapolis. Pre-Seed. The physician-LP network is the clinical and research adoption base; the committee stack is bypassed at the bench.

Clear Health is an AI-powered, HIPAA-compliant pre-service billing platform headquartered in Nashville. Seed+. Physician-owner practices are the deployment site; the workflow is installed where the patient encounter starts, not where hospital revenue cycle ends.

CompliantRx is an AI-powered compliance and referral routing platform for the durable medical equipment ecosystem, headquartered in Coral Springs. Seed. The physician is the source of the referral; physician-owner adoption is the channel that durable medical equipment vendors and prescribers actually use.

Three companies.
Three sectors.
One adoption mechanism.

None of the three is running the hospital procurement playbook, and none of the three is burning runway on the committee stack.

---

The Counterargument

The honest concern from founders is the captive-audience critique. If physician LPs use a tool because they own the fund that owns the company, the adoption data masks product quality. The market will not validate on the other side.

The response runs two ways. First, the physician’s primary duty is to the patient and to time. A practicing physician will not use a tool that harms workflow or adds meaningful cognitive load, regardless of equity exposure. The clinical rejection rate inside the LP network is a stronger signal than the approval rate inside a hospital committee, because the LP is the end user and the hospital committee is a procurement proxy.

Second, the scalability concern is real. A tool that works within the PhyCap LP network is not automatically one that scales across 900,000 US physicians. The response is that the network is a clinical-validation environment, not the addressable market. Adoption within the network produces the usage-data asset, retention, time-per-encounter, and payer-landscape performance that institutional Series A and B capital underwrites against. The handoff from physician-anchored seed to institutional growth is structural, not a rescue. Founders who frame the LP network as the market will overstate the thesis; founders who frame it as the validation layer will price the Series A correctly.

The Implication

For a founder selling into physicians, the Series A cap table is the instrument that preserves the compression the seed round produced. A physician-anchored seed investor who produced the clinical-adoption data. An institutional Series A lead that underwrites the growth math against the usage asset. A strategic operator who understands payer dynamics and can open the enterprise expansion path outside the original LP network. Three shareholders, three diligence perspectives, one compressed sales cycle carried forward. That is the architecture the growth-stage capital will underwrite against, and it is the architecture the seed round has to be designed to produce. The death march does not have to be run. It has to be designed around.

Work With PhyCap Fund

Fund I closes May 31, 2026.

Physicians Capital Fund deploys $100,000 to $500,000 checks into Pre-Seed - Series A healthcare companies across three verticals:

• Clinical Care Delivery Workflow Optimization

• Software as a Medical Device

• Women’s Health

The thesis is structural. Healthcare’s most durable returns accrue to companies built with physicians, not at them. Capital sourced from the people closest to the point of care sees what committees and consultants miss.

Hundreds of physicians and healthcare leaders have already committed. Fund I hard closes end of business May 31, 2026.

If you practice medicine, operate a healthcare business, or allocate capital in the space, Fund I was built for you.

Invest with PhyCap Fund I →

Email: info@46.capital
Socials: LinkedIn X

Glossary

Hospital CFO Death March. The 12-to-24-month procurement and approval cycle a seed-stage healthcare company navigates to convert a hospital pilot into committed enterprise revenue. The cycle consumes seed-stage runway and converts at single-digit to low-teen rates.

Committee Stack. The six-to-ten-committee approval sequence inside a hospital system that gates any enterprise vendor contract. Includes clinical review, technology integration, clinical informatics, nursing workflow, compliance, revenue cycle, vendor risk, finance, and, at academic systems, research integration.

Counterparty Credit. The financial strength of the entity on the other side of a contract. A hospital system with downgraded bond ratings cannot underwrite durable enterprise spend, regardless of pilot clinical outcomes.

Physician-Anchored Capital. Venture capital whose limited partner base is composed primarily of practicing physician-owners. The LP base serves as the clinical-validation and adoption environment for portfolio companies.

Physician-LP Cap Table. A capitalization structure where practicing physicians hold the seed-stage equity. The buyers and users of the product are the same people who underwrote the round.

Pilot-to-Enterprise Conversion Rate. The percentage of hospital pilots that convert to committed multi-year enterprise contracts. Industry conversion runs in the single digits to low teens.

Sales Cycle Compression. The collapse of the procurement timeline from 12 to 24 months at the hospital committee level to 2 to 8 weeks at the physician-owner practice level.

Customer Acquisition Cost (CAC). The fully loaded cost of acquiring a paying customer, inclusive of sales, marketing, and cycle-time burn. CAC is the primary lever that determines seed-stage runway survival.

Clinical Validation Environment. A network of physician-owners used to generate retention, workflow, and payer-landscape data that institutional growth capital underwrites against. The network is not the addressable market.

Usage-Data Asset. The retention, time-per-encounter, and payer-performance data a portfolio company generates inside the clinical validation environment. The asset is what a Series A lead prices against.

Series A Cap Table Architecture. A three-shareholder structure that preserves seed-stage compression into growth-stage capital. Includes the physician-anchored seed investor, the institutional Series A lead, and the strategic operator.

PhyCap Innovation Circle. The adoption architecture that the PhyCap Fund uses to route portfolio companies into practicing physician-owners for clinical validation and operational deployment.

Arkansas Pivot. The first public reference deployment of the PhyCap Innovation Circle at the regional scale. Routed Apian through the Northwest Arkansas corridor and UAMS, bypassing standard academic medical center procurement.

Apian. Healthcare logistics company in the PhyCap portfolio. First reference deployment of the PhyCap Innovation Circle architecture.

UAMS. University of Arkansas for Medical Sciences. Academic medical center in Little Rock. Apian integration point in the Arkansas Pivot.

Sources

1. Moody’s Investors Service. Rating action on OU Health following 2025 state intervention.

2. Olive AI shutdown. Company wind-down announcement, October 2023. Bloomberg, Axios coverage.

3. Pear Therapeutics bankruptcy. Chapter 11 filing, April 2023. SEC filings; Fierce Biotech coverage.

4. Babylon Health collapse. US subsidiary bankruptcy, August 2023. Financial Times, Reuters coverage.

5. Forward Health closure. Company shutdown announcement, November 2024. TechCrunch, Forbes coverage.

6. Hospital pilot-to-enterprise conversion rate (single digits to low teens).

7. Segment-level failure data (telemedicine 30-40%, AI CDS 30%, point-of-care diagnostics 40-50%).

8. Seed-stage healthcare burn rate of $400K to $700K per month. [Inference: industry-standard range based on operator observation. If presented as fact, cite Bessemer or Silicon Valley Bank healthcare benchmarks.]

9. 2-to-8 week physician-owner adoption cycle. PhyCap Fund internal operator data. First-party reference.

Disclosure

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

The people writing those checks had never written a clinical note, billed a CPT code, or sat through an EHR go-live.

That’s not a bad-luck problem.
That’s a picker problem.
And it’s why physician-led capital is the only healthcare allocator left with a structural edge.

WHAT TO EXPECT IN THIS ARTICLE

• The condition: three failure modes that have quietly killed a decade of generalist healthcare VC bets

• The data: segment-level failure rates across the seven largest digital health categories, and why the highest failure rate sits in the segment with the most traditional capital

• The thesis: why physician-led diligence eliminates the one failure mode that sets terminal value

• The counterargument from Sand Hill Road, and why it collapses on contact with twenty years of segment data

The allocation question every physician LP and institutional allocator must answer this cycle.

Healthcare venture returns depend more on the picker’s quality than the founders’. For 20 years, digital health’s dominant picker has been a former banker or MBA, never present where the product is used. This is the structural defect at the top of the capital stack, and it compounds across the sector’s return distribution.

The data on category-level failure rates are already in evidence. Across the seven largest digital health segments, observed venture failure rates now range from 30% to 70%. The highest failure rate, AI clinical decision support at roughly 70%, sits in the segment with the highest concentration of traditional venture capital. This is not a coincidence. It is the picker problem expressed as a return distribution.

We call this the Picker-Incubator-Distributor model. Terminal value of a healthcare investment is set at the picker stage, improved at the incubation stage, and realized at the distribution stage. Generalist healthcare VC is weak at all three, and it is worst at the one that matters most.

The Condition

US venture capital has cycled more than $100 billion through digital health since 2018, per Rock Health annual funding reports. A meaningful share of that capital was allocated by investors who have never written a clinical note, billed a CPT code, or sat through an EHR go-live. The result is a category that looks durable on a pitch deck and fails at the first high-volume shift.

Three failure modes recur.

Clinical workflow blindness. A tool that adds sixty seconds of cognitive load per patient encounter is not an adoption candidate. It is an operational liability. Generalist VCs mistake technical viability for clinical adoptability. They underwrite ARR projections against a market that rejects the product within ten minutes of real use. This is why point-of-care diagnostics and AI hospital operations products collectively fail at 50-60%, the models do not fit actual workflows.

The hospital logo fallacy. Traditional investors read a pilot contract with a major system as a durable revenue signal. In practice, hospital pilot revenue is often a vanity metric or a government-subsidized bailout of a system operating at or near junk credit ratings. The recent OU Health transaction is instructive: private operators were exiting, while the state stepped in to pay 10% above the asking price for a system that Moody’s subsequently downgraded. Companies chasing hospital logos end up anchored to counterparties whose balance sheets will not underwrite follow-on spend.

Billing and coding ignorance. Investors who do not understand the Independent Dispute Resolution process, the shifting arithmetic of payer-side economic pressure, and the regulatory levers that move reimbursement overnight will back business models that unwind when the rules change. The B1/B2 statistical test, the lockpick that enabled a decade of state Medicaid financing, was killed by CMS final rule on January 29, 2026, with states given until end of CY 2026, and in some cases up to three years, to transition. Startups underwritten against that revenue base are now on a wind-down clock. This is not a black swan. It is the foreseeable outcome of a picker who never modeled the policy surface.

Venture Failure Rates by Segment

Each row describes a segment where generalist VC is the dominant capital source, and where the picker could not read the failure mode before writing the check.

The Thesis

Physician-led capital identifies failure modes before the check. This edge appears at the picker stage in a way that cannot be replicated later.

When a founder pitches an AI workflow tool to PhyCap, the diligence team includes Paul Slosar, MD (29 years, orthopedic spine, former CMO of Titan Spine), Fred Liss, MD (34 years, Chairman of Physician-Led Healthcare for America), and Robin Noble, MD (25 years, OB/GYN). Eighty-eight years of combined clinical time on the diligence call, pulled from a broader PhyCap network of 168+ years of physician leadership. The question of whether the product survives its first ten minutes of clinical use is answered before the term sheet is drafted.

The math of the edge is straightforward. In a category where the base-rate failure is 60% driven by workflow integration, an allocator who can reliably eliminate workflow-integration risk at the picker stage is not offering a slightly better diligence process. The allocator is operating against a different return distribution. If clinical diligence removes half the workflow failures in the underwritten book, the base-rate-adjusted return at the seed stage rises materially relative to a generalist portfolio. That delta is before any downstream incubation or distribution advantage.

The second source of edge is that clinical validation is increasingly the gating event for follow-on capital. Series A valuations are no longer set by the size of the check. They are set by the depth of the clinical footprint. A seed-stage company with workflow integration across five member practices and documented adoption data is, on a risk-adjusted basis, a more durable Series A candidate than one with the same ARR and a hospital-system logo. The picker that structures the seed round with clinical validation baked in is the picker that sets the Series A terms.

The Counterargument

The strongest objection from Sand Hill Road is that physicians make poor investors because they are too close to the problem. The argument runs that clinical operators lack institutional investment discipline, cannot read a cap table, and confuse product utility with enterprise durability. Taken seriously, this is the main reason physician-led capital was absent from institutional portfolios for a generation.

The response is structural. Physician-led capital is not a replacement for institutional discipline. It is a complement to it. PhyCap partners with FortySix Capital and operator leadership to pair clinical vetting with institutional investment rigor. Clinical expertise identifies utility. FortySix Capital validates the business. The diligence process explicitly combines both.

The critique also flattens the diligence problem. It assumes the institutional discipline gap is the binding constraint on returns. Twenty years of segment-level failure rates say otherwise. The binding constraint has been the picker’s inability to assess clinical adoptability, not the picker’s inability to assess unit economics. The generalist fund has the second skill and lacks the first. The physician-led fund, structured correctly, has both.

The remaining concern, that clinical utility does not translate to scalable enterprise value, is the incubation and distribution problem, not the picker problem. It is the subject of subsequent analysis. At the picker stage, the question is narrower: which allocator can read which product will survive the clinic? The data says one allocator type reads it well, and the other has been reading it at a 30-to-70% error rate for a decade.

The Allocation Implication

The picker determines terminal value. That is not a rhetorical claim. It is the structural finding.

For a physician LP evaluating where to allocate this year, the question is not whether venture capital belongs in the portfolio. The question is whether the picker doing diligence on the capital you commit has ever been in the room where the product is used.

Where the answer is no, the return distribution already describes what follows.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K–$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com | Email: info@46.capital | Socials: LinkedIn X

GLOSSARY

Picker. The capital allocator who decides which company gets the check. In venture, the picker determines terminal value — not the founder, not the incubator, not the distribution partner.

Picker-Incubator-Distributor (P-I-D) model. A framework for evaluating where a venture investment’s terminal value is actually set. Value is set at the picker stage (company selection), improved at incubation (product and team development), and realized at distribution (customer scale). Weak pickers cannot be rescued downstream.

Generalist healthcare VC. A venture capital firm that deploys into healthcare without a clinical operator making the investment decision. Historically: former bankers, MBAs, and technology investors pattern-matching healthcare to SaaS.

Physician-led capital. Investment capital where clinicians with active or recent practice experience sit at the diligence table and have decision authority over the check.

Clinical workflow blindness. The inability of a non-clinical investor to recognize that a product which adds cognitive load to a patient encounter will be abandoned on day one, regardless of technical merit.

Hospital logo fallacy. The mistake of treating a pilot contract with a marquee hospital system as proof of durable enterprise revenue. Pilot revenue is often non-recurring, loss-leading, or funded by government bailouts to systems at junk credit ratings.

EHR go-live. The day a hospital or practice cuts over to a new electronic health record system. Universally regarded as the worst day of a clinician’s year. Attending one is a basic qualification for anyone underwriting clinical software.

Independent Dispute Resolution (IDR). The federal process created by the No Surprises Act to arbitrate out-of-network payment disputes between clinicians and insurers. Reimbursement arithmetic for entire segments of medicine turns on IDR outcomes.

B1/B2 statistical test. The Medicaid financing mechanism that states used for over a decade to generate federal matching dollars on provider taxes. Killed by CMS final rule on January 29, 2026, with a transition window through end of CY 2026 and, in some cases, up to three years. Any digital health company underwritten against a revenue base tied to B1/B2 arithmetic is now on a wind-down clock.

Base rate. The underlying historical failure rate of a category. In AI clinical decision support, the base rate of venture failure is approximately 70%. A picker’s edge is measured against this rate, not against a hypothetical.

Return distribution. The full spread of possible investment outcomes across a portfolio. Institutional returns are not a function of any one deal; they are a function of the shape of the distribution across the book. The picker sets the shape.

Follow-on capital. Capital raised in subsequent financing rounds (Series A, B, C) after the seed check. The gating event for follow-on capital is increasingly clinical validation, not ARR.

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

A health system purchases an AI diagnostic tool. The tool needs patient data from the EHR. The integration takes nine months, costs six figures, and breaks during the first software update.

The AI tool works.
The infrastructure does not.
This is the market.

IN TODAY’S ARTICLE:

+ Why the funding gap between healthcare AI and interoperability represents a pricing inefficiency, not a quality signal

+ Where EHR integration continues to fail at the point of care, and what that failure reveals about the infrastructure layer

+ How FHIR and TEFCA mandates create a defined regulatory pathway that healthcare AI lacks

+ Why physician investors carry a diligence advantage in evaluating interoperability solutions that generalist VCs cannot replicate

Glossary at the bottom of today’s article.

THE FUNDING GAP IS THE SIGNAL

Healthcare AI dominates the venture narrative. The pitch decks are compelling. The demos are impressive. The valuations reflect that enthusiasm. But beneath every AI application in healthcare sits an infrastructure layer that determines whether the application functions in a real clinical environment.

That infrastructure layer is interoperability*. And it is raising capital at a significant discount to its AI peers.

U.S. digital health funding totaled $14.2 billion in 2025. AI-enabled companies captured 54% of that total, up from 37% in 2024. Meanwhile, Health Management Solutions' funding surged 70% in 2025.

The infrastructure categories are growing faster on a percentage basis, but the absolute dollars and the valuation multiples still favor the AI narrative. Interoperability companies often have shorter implementation timelines, more predictable revenue, and a regulatory framework that is actively mandating adoption.

The pricing gap reflects narrative preference rather than fundamental analysis. Venture capital is paying a premium for the AI story and applying a discount to the infrastructure it requires. For investors who evaluate based on fundamentals rather than narrative momentum, that gap is actionable.

WHERE INTEGRATION FAILS AT THE POINT OF CARE

Physicians experience interoperability failure every day. A specialist receives a referral. The referring physician’s notes are in a single EHR system. The specialist uses a different system. The patient’s medication list, imaging history, and lab results are fragmented across multiple platforms.

The result is duplicated tests, delayed treatment decisions, and clinical risk. According to KLAS Research, only 44% of clinicians agree that their EHR provides the expected level of integration with external organizations. 47% report they cannot quickly find important patient information from outside organizations. The problem is not that the data does not exist. The problem is that it does not move.

20% of EHR system installations are considered outright failures. More than 50% either fail or are not properly utilized. That rate persists despite two decades of investment in health information exchange*. The reason is structural. EHR vendors have historically treated data portability as a competitive threat rather than a product feature. Interoperability companies build around that resistance, not with it.

Every physician who has waited for patient data to load from a referring system understands the interoperability problem in a way no pitch deck can convey. PhyCap’s network exists because daily clinical friction serves as a diligence filter — it separates products built for clinical environments from those built for demo rooms.

FHIR AND TEFCA CREATE A REGULATORY FLOOR

Two regulatory developments have changed the interoperability landscape. The first is the widespread adoption of FHIR* (Fast Healthcare Interoperability Resources), an API-based standard that enables structured data exchange between health systems. The second is TEFCA* (Trusted Exchange Framework and Common Agreement), ONC’s framework for establishing a national health data exchange network.

FHIR adoption has accelerated. 71% of respondents in the 2025 State of FHIR survey report that FHIR is actively used in their country, up from 66% in 2024. 73% of national regulations now mandate or advise the use of FHIR. The standard provides a common technical language that reduces the custom integration work historically required for each system-to-system connection.

TEFCA is building the governance layer on top of that technical standard. As of February 2026, nearly 500 million health records have been exchanged through TEFCA, up from roughly 10 million in January 2025. Over 71,000 sites now participate through 11 QHINs. The framework designates Qualified Health Information Networks (QHINs) as trusted intermediaries for nationwide data exchange.

Together, FHIR and TEFCA create something that healthcare AI does not yet have: a defined regulatory pathway that mandates adoption. AI regulation in healthcare remains fragmented and evolving. Interoperability regulation is specific, funded, and moving forward on a published timeline.

For venture investors, this distinction matters. A company building on FHIR and TEFCA rails has a regulatory tailwind pushing adoption. An AI company faces a regulatory environment that could accelerate or constrain its market depending on which agency acts first. The interoperability bet carries less regulatory uncertainty. The market has not priced that in.

The Revenue Quality Argument

Interoperability companies tend to generate revenue through per-transaction fees, subscription access to data exchange networks, or integration-as-a-service contracts. That revenue is recurring and usage-based, increasing as more systems connect to the network.

The network effects* in interoperability are real and underappreciated. Each new connection to a health information exchange increases the network's value for every existing participant. A hospital that joins a data exchange network makes that network more valuable to every physician practice, lab, and pharmacy already connected to it.

AI companies in healthcare face a different revenue dynamic. Many sell on a per-seat or per-use basis, with value tied to model performance. Model performance depends on the quality and volume of the training data. That depends on interoperability infrastructure.

This creates a dependency chain that the venture market has largely ignored. Healthcare AI revenue growth is constrained by the interoperability layer beneath it. Investing in interoperability is not a bet against AI. It is a bet on the infrastructure that AI requires.

The venture market prices narrative momentum. Physician investors price clinical infrastructure. When AI tools fail at the integration layer, the physicians in the PhyCap network already know why — and that information asymmetry is where better entry points originate.

WHY PHYSICIAN DILIGENCE CHANGES THE EVALUATION

Interoperability is technical, but evaluating interoperability products is clinical. A physician can assess whether a data exchange solution delivers the right information, in the right format, at the right point in the clinical encounter. That assessment requires understanding the clinical workflow, not just the API architecture.

Generalist VCs evaluate interoperability companies on integration count, transaction volume, and technical scalability. Those metrics matter. They do not answer the question that determines long-term adoption: does the physician actually get the data they need, when they need it, in a format they can act on?

Physician investors ask that question instinctively. They have lived on the receiving end of interoperability promises that failed in practice. They know the difference between a product that moves data between systems and a product that delivers clinical insight at the point of care.

THE PRICING INEFFICIENCY, RESTATED

Markets misprice assets when narrative overrides analysis. Healthcare AI carries a narrative premium. Healthcare interoperability carries a narrative discount. The healthcare interoperability solutions market is projected to reach $9.57 billion by 2031, growing at a CAGR of 11.27% (source 7). The fundamentals favor the discounted asset: regulatory clarity, revenue predictability, and the necessity of infrastructure.

This does not mean every interoperability company is a good investment. It means the category deserves a valuation framework that accounts for its regulatory advantages, revenue quality, and structural position in the healthcare technology stack. Physician investors who evaluate clinical workflow fit within that framework have a diligence advantage that leads to better entry points and stronger portfolio outcomes.

The interoperability gap is still open. In both the clinical sense and the investment sense.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K–$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital
LinkedIn: linkedin.com/company/phycap
X: x.com/physicianscap

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

GLOSSARY

Interoperability: The ability of different healthcare information systems to exchange, interpret, and use data. In practice, it means patient data moving between EHRs, labs, pharmacies, and payers without manual intervention.

EHR (Electronic Health Record): The digital system where patient medical data is stored, accessed, and updated by clinical staff.

Health information exchange (HIE): The electronic transfer of clinical and administrative data between healthcare organizations. HIE can refer to both the act of exchanging data and the organizations that facilitate that exchange.

FHIR (Fast Healthcare Interoperability Resources): An API-based standard developed by HL7 International for exchanging healthcare data electronically. FHIR enables structured, standardized data queries between systems without requiring custom point-to-point integrations.

TEFCA (Trusted Exchange Framework and Common Agreement): A federal framework developed by the Office of the National Coordinator for Health IT (ONC) to establish a nationwide health data exchange infrastructure. TEFCA designates trusted networks to facilitate secure data sharing.

Qualified Health Information Networks (QHINs): Organizations designated under TEFCA to serve as trusted intermediaries that facilitate nationwide health data exchange. QHINs connect health systems, payers, and public health agencies through a common governance framework.

Network effects: The phenomenon where a product or service becomes more valuable as more users join. In interoperability, each new system connected to an exchange increases the data available to all connected participants.

SOURCES

1. Rock Health, “2025 year-end digital health funding overview” (Jan 12, 2026)
2. Galen Growth, “U.S. Digital Health Funding 2025” (Jan 29, 2026)
3. EHR in Practice, “10 EHR failure statistics” (Oct 29, 2024)
4. KLAS Research, “EHR Interoperability 2024: Clinician Needs Still Not Being Met” (Sep 9, 2024)
5. Firely & HL7 International, “The State of FHIR in 2025” (June 25, 2025)
6. ASTP/ONC Press Release, TEFCA exchange and participation data (Feb 11, 2026)
7. Mordor Intelligence, Healthcare Interoperability Solutions Market forecast (2026)

As a renter, you aim to avoid damage marks during the exit inspection. An owner proactively prioritizes value creation, shifting from subsistence to improvement. Owners add window treatments to reduce electric costs, cultivate garden beds for curb appeal, and leave the faucets dripping on cold nights to protect unseen pipes.

Traditional healthcare VC engages clinical experts on a one-off basis, asking for feedback on one deal at a time from experts who don’t have a stake in the outcome. As a result, these experts have a “renters” mentality: to avoid damage, they may err on being overly academic or safe (i.e., hypercritical) in their assessment. Their compensation incentivizes uncovering flaws, and they lack both the influence and longevity to create opportunities on behalf of the investment.

Physicians Capital Fund (PhyCap) is different. It’s built on the “owner” mindset. Clinical experts comprise the fund’s DNA, the limited partner (LP) base: these LPs own the failures and directly benefit from the Fund’s successes. They aren’t just looking for reasons to say “no” but are actively thinking about how to clear or redesign hurdles into opportunities. An ad hoc consultant may tell you a window is drafty, but it’s up to the owner to apply the elbow grease to fix it. An LP’s commitment to reducing burn rates, cultivating customer leads, and building scalable infrastructure is rivaled by that of only the founder.

The Challenge: Exception-as-the-rule “Spectator” Capital

The healthcare and investment worlds have seen what happens when capital deployment is disconnected from clinical reality. Theranos raised nearly $1.3 billion over 12 years with a catastrophic outcome, siphoning capital away from promising technologies, largely because “spectators” in the boardroom couldn’t spot flaws in the lab.

Today, we face a similar systemic risk that limits our ability to translate the best healthcare solutions into clinical and community settings: geographic capital isolation. Seventy percent of healthcare innovation capital is sequestered in just three coastal hubs, representing only 10% of the US population. One state alone, California, sequestered nearly 50% of US VC in 2024. This physical distance between investment and deployment environments creates a geographical rift in the clinical perspectives that develop, deploy, and fund new healthcare technologies.

Nationally, the physician-to-patient ratio is 1:336 (1:213 in Massachusetts, home to capital hotspot Boston), but in rural environments, that ratio balloons 10x to ~1:3,000 and is accentuated by geography, with a 1:3,441 in the South and 1:1,979 in the Northeast. Additionally, 30% of rural hospitals are “vulnerable to closure” and 60% lack labor and delivery care. It isn’t difficult to imagine why a technology developed in a specialist-heavy Boston clinic may lack luster in a resource-constrained rural hospital. By relying on coastal SMEs, traditional VC ignores the “pebbles in the shoe’’ felt by the rest of the nation. Both technologies may be valuable, but their impact is not equal.

The Solution: Moving from SME-as-Consultant to SME-as-Owner

PhyCap operates from the conviction that geographical diversity and variety in clinical expertise codes DNA that translates into clinically functional solutions. While renters (i.e., one-off subject matter experts (SMEs)) look for problems; SME owners look for solutions.

PhyCap’s DNA is coded by LPs nationwide who represent expertise across the full healthcare value chain, including clinicians who grasp deployment realities, operators who understand scale, execs who make purchasing decisions, and manufacturers who recognize what’s actually buildable. This creates a capability continuum: just as DNA progresses through transcription and translation machinery before it’s folded into functional protein, the full-spectrum of PhyCap LP expertise orchestrates seamless support as a minimum viable product (MVP) scales to commercial production.

Below are a few examples of how PhyCap LPs partner with portfolio companies to facilitate product/market fit and widespread commercial adoption:

• Beta Testing: Refining products in diverse, real-world clinical workflows.

• Translation: Turning trendy tech into functional, easily adoptable instrumentation. This feature is especially important as AI becomes more pervasive, initiating a new reality to chart human and/or machine interactions in clinical environments.

• Commercial Shortcuts: Anticipating fabrication challenges before mass production begins.

The SBIR/STTR Blueprint

The Small Business Innovation Research/Small Business Technology Transfer program (SBIR/STTR) has already proven the value of including clinical experts in investment decisions. The SBIR/STTR review process is rooted in rigorous SME input out of necessity. These early-stage, high-risk/high-reward technologies are fresh off the research bench and still enshrined in SME jargon.

A 2019 study of National Cancer Institute (NCI) SBIR/STTR investments showed that $787 million in funding (over ten years) generated:

• 53% of recipient companies generating revenue, totaling $9.1 billion in total sales

• $26.1 Billion in total economic impact

• 11.6x Multiple on invested capital (MOIC) proxy (calculated as $9.1 B / $0.787 B)

While we cannot directly compare early-stage federal grants to early-stage venture capital, the contrast is clear: the NCI’s 11.6x MOIC proxy, compared with the 3x–5x MOIC typical of top-tier venture capital firms, emphasizes the positive impact of SME involvement.

Smart Thesis

Expertise is one half of PhyCap’s strategy. The other key component of PhyCap’s DNA is an investment thesis that enables the fund to bypass speculative “shiny objects” with long, uncertain return timelines and instead focus on practical, clinical solutions. By concentrating on Women’s Health and Health Inequity, Software as a Medical Device (SaMD), and Clinical Care Delivery Workflow Optimization, PhyCap targets top growth, high-utility segments of the $9.34 trillion global healthcare market.

The Fund’s prioritization of Women’s Health and Health Inequity (5.3% CAGR) is a strategic play for one of the largest healthcare segments (~50%) of a ~$5.5 trillion US market. SaMD (23.6% CAGR) enhances clinical decision-making without the astronomical “burn” of high-risk hardware. Combined, these two technology focus areas empower PhyCap to claim a piece of the anticipated $1 trillion shift (by 2035) from outdated administrative and infrastructure spending to AI-enabled personalized medicine. Through Clinical Care Delivery Workflow Optimization (16.6% CAGR), PhyCap prioritizes technologies that improve the day-to-day efficiency and effectiveness of medical practice, removing the “pebbles in the shoes’’ that contribute to provider burnout. When paired with the clinical LP network, these investment areas aren’t just smart; they serve our country’s future by unburdening clinical staff and increasing access to care that works where it’s deployed.

This pragmatic focus reflects PhyCap’s Midwest heritage and “Dust Bowl Mentality.” Shaped by historical periods of economic hardship (i.e., the Dust Bowl), the Midwest prioritizes grit, resilience, and resourcefulness, and PhyCap’s strategy reflects that commitment to enduring ingenuity. PhyCap prioritizes recession-resilient technologies that remain relevant regardless of the economic climate. In a recession, an expensive elective treatment takes second place to sustainability; a workflow solution that improves the bottom line and saves clinician time gains attractiveness.

The Neural Network of Healthcare’s Future

Clinical perspective must be integrated across the commercialization pathway, from inception, to development, to deployment. PhyCap offers clinical experts the opportunity to influence and own the future of healthcare by influencing both development and deployment. The Fund’s neural network comprises a diverse, geographically representative set of clinical experts committed to bringing transformational products to providers and patient communities nationwide. This clinic-first DNA encodes a fund that offers both capital and endorsement by a network of partners that will catapult portfolio companies to success.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

If you’re a physician or healthcare professional interested in getting involved, book an intro call with our team here.

If you’re a founder building a healthcare company, pitch us here.

Website: PhyCapFund.com
Email: info@46.capital

LinkedIn: Follow us on LinkedIn
X: Connect with us on X

DISCLOSURE

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

Between 2000 and 2024, 276 women’s health companies exited, generating a cumulative value of more than $100 billion.

Twenty-seven of those were billion-dollar transactions.

The category that venture capital still calls “emerging” has a longer track record than most sectors VCs consider mature.

IN TODAY’S ARTICLE:

• Women’s health has generated a cumulative exit value of over $100 billion across 276 transactions over 25 years, a track record that contradicts the “emerging market” label.

• Venture capital investment in women’s health reached $2.6 billion in 2024, a 55% year-over-year increase, while the broader femtech* market is projected to reach $267 billion by 2035.

• The misclassification of women’s health exits across oncology, diagnostics, and chronic disease has obscured the category’s true scale and created pricing inefficiencies for investors.

• For physician capital allocators, clinical expertise in women’s health conditions represents a durable competitive advantage in evaluating a category that generalist investors have systematically undervalued.

Glossary at the bottom of today’s article.

The Narrative Versus the Data

The women’s health investment category has carried one label for longer than almost any other in healthcare venture: emerging.

The label persisted through 276 company exits. It persisted through $100 billion in cumulative exit value. It persisted through 27 billion-dollar transactions spanning diagnostics, devices, therapeutics, and digital health.

In January 2026, AOA Dx presented the first comprehensive analysis of women’s health exits at the J.P. Morgan Healthcare Conference. The report, titled “Follow the Exits,” tracked every women’s health company exit between 2000 and 2024. The conclusion was direct: women’s health is a substantial, established segment of healthcare with a long track record of value creation.

The data supports it.
The market is now pricing it in.

The Exit Record

The AOA Dx report revealed a category that strategic acquirers have valued for decades while venture investors debated whether it was ready.

Strategic buyers accounted for 91% of women’s health exits. Only 9% occurred through IPOs*. Repeat acquirers demonstrated sustained commitment to the category. Hologic completed 22 acquisitions with a total deal value of $14.16 billion. CooperSurgical made 21 acquisitions totaling $4.5 billion.

In October 2025, Blackstone and TPG agreed to acquire Hologic for up to $18.3 billion in enterprise value*, taking the company private. The deal represented a 46% premium to the pre-announcement share price. If included in the AOA Dx dataset, which covered exits through 2024, the total cumulative women’s health exit value approaches $120 billion.

The Hologic transaction alone is more than seven times the total annual venture capital investment in women’s health.

Blackstone, the world’s largest alternative asset manager with $1.2 trillion in assets under management, made a directional bet on women’s health diagnostics and imaging.

This is institutional conviction at scale.

Generalist VCs evaluated women’s health through a reproductive care lens for two decades. Physicians who treat women across cardiology, endocrinology, and internal medicine saw the full clinical picture.

Physicians Capital Fund invests in women’s health startups at Seed and Series A because that clinical perspective is the diligence edge in a category the market systematically undervalues.

Subscribe now

The Misclassification Problem

One of the most significant findings in the AOA Dx analysis is that the women’s health category has been systematically understated due to legacy misclassification.

The traditional definition focused narrowly on reproductive care: fertility, pregnancy, and menopause. The AOA Dx report applied an expanded definition organized into three tiers. Conditions unique to women, such as reproductive health and menopause. Conditions that manifest differently due to sex-based biology, such as cardiovascular disease and Alzheimer’s. Conditions that disproportionately affect women, such as autoimmune disorders and osteoporosis.

According to McKinsey data cited in the report, only 5% of the overall disease burden affecting women is exclusive to female biology. The remaining 95% comes from conditions that affect women disproportionately or differently. Yet these conditions have historically been classified under oncology, neuroscience, diagnostics, or chronic disease rather than women’s health.

The result: decades of exits that should have been tracked as women’s health were counted in other categories. Alzheimer’s disease affects women at twice the rate of men, yet Alzheimer’s companies were classified under neuroscience. Breast cancer diagnostics companies were classified as oncology companies. The cumulative effect is a category whose true scale has been hidden in plain sight.

For investors, misclassification creates pricing inefficiency. When a market appears smaller than it is, capital underallocates. When the data is corrected, capital reprices. That correction is underway.

The Capital Acceleration

The exit data tells the historical story.
The venture data tells the current one.

Women’s health venture capital investment reached $2.6 billion in 2024, a 55% year-over-year increase that outpaced growth in the broader healthcare industry, according to Silicon Valley Bank’s 2025 Innovation in Women’s Health Report. When the category expanded to include all health issues disproportionately affecting women, total investment rose to $10.7 billion.

The global femtech market was valued at $63.1 billion in 2025 and is projected to reach $267 billion by 2035, representing a compound annual growth rate* of more than 15%, according to Astute Analytica.

As recently as 2023, only 4% of the $26.5 billion invested in healthcare companies went to women’s health. The 55% increase in 2024 signals a correction, not a trend. Capital is flowing because the data on returns supports it.

The stage composition is also maturing. In 2023, seed and Series A* deals made up 83% of women’s health investments. By 2024, that figure had dropped to 70%, indicating that more companies were progressing to growth-stage financing. The pipeline is deepening.

The misclassification of women’s health created a pricing gap that persisted for 25 years. Now that the data has been corrected, capital is repricing.

Physicians Capital Fund backs women’s health startups at Seed and Series A because physicians who treat these patients daily can evaluate clinical need, workflow fit, and adoption potential before a generalist investor reads the market report.

Subscribe now

Midi Health: The Clinical Model at Scale

Midi Health’s $100 million Series D and billion-dollar valuation in February provide a case study in what scaled women’s health clinical delivery looks like.

The company, launched in 2021, focused on perimenopause and menopause care. It has since expanded into what it describes as “lifelong care,” encompassing cardiology, obesity management, autoimmune survivorship, and longevity. Midi now serves more than 25,000 patients per week across all 50 states through a network of over 500 clinicians spanning OB/GYN, internal medicine, cardiology, endocrinology, and other specialties. Insurance coverage reaches more than 45 million women nationwide. Total patients served exceed 230,000.

The clinical outcomes data is the foundation. Midi reports a 28 percentage-point increase in breast cancer screening adherence, an 11 percentage-point increase in colorectal cancer screening adherence, and up to 13% lower total cost of care compared to a matched group.

For physician investors, the Midi model demonstrates three principles. First, clinical quality drives adoption: women return because the care improves outcomes. Second, technology serves the clinician: Midi’s AI handles chart analysis, scheduling, and documentation while physicians focus on diagnosis and treatment. Third, the insurance-backed model creates sustainable unit economics*: this is scalable infrastructure, not a cash-pay concierge service.

Goodwater Capital led the round, a consumer technology investor whose portfolio includes Spotify and Twitter. Goodwater’s participation signals that the market evaluates Midi as a consumer healthcare brand, not a niche telehealth play. Additional investors include GV (Google Ventures), Foresite Capital, Serena Ventures, Emerson Collective, and McKesson Ventures.

The Structural Thesis

The women’s health investment thesis rests on three structural pillars.

The clinical need is massive and undertreated. 2 million women enter menopause each year in the United States. Untreated symptoms cost an estimated $25 billion per year in medical expenses and lost productivity. Beyond menopause, the expanded definition encompasses cardiovascular disease, autoimmune conditions, osteoporosis, Alzheimer’s, and oncology, conditions that affect billions of women globally and remain under-researched relative to their burden.

The exit data is established. Over $100 billion in cumulative exit value over 25 years. Strategic acquirers, not IPOs, drive exits, making returns less dependent on public market sentiment. Repeat acquirers like Hologic and CooperSurgical confirm sustained strategic demand.

The capital is accelerating from a low base. When only 4% of healthcare venture capital went to women’s health in 2023, the upside from reallocation is significant. The 55% increase in 2024 and the Gates Foundation’s $2.5 billion pledge over five years for women’s health research confirm that both private and institutional capital are repricing the category.

For physician capital allocators, the advantage is clinical. Evaluating a woman’s health startup requires understanding the conditions it treats, the workflows it operates within, and the reimbursement structures that determine sustainability. Physicians Capital Fund invests in this category at Seed and Series A because a network with clinical experience across OB/GYN, internal medicine, cardiology, and endocrinology evaluates these companies through a lens that financial analysis alone cannot provide. The fund recognized this structural opportunity before the market priced it in. The data now confirms the thesis.

WORK WITH PHYCAP FUND

Physicians Capital Fund has made two investments and is in the final phase of closing. We continue to accept introductions from qualified physicians interested in the fund. Email: info@46.capital

DISCLOSURE:

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

GLOSSARY

Femtech: Technology-based products and services focused on women’s health, spanning fertility, pregnancy, menopause, and conditions that disproportionately affect women. The market has expanded beyond reproductive care to encompass the full spectrum of women’s health needs.

IPO (Initial Public Offering): The process by which a private company offers shares to the public for the first time, listing on a stock exchange. In women’s health, only 9% of exits occurred through IPOs, with strategic acquisitions dominating.

Enterprise Value: The total value of a company, including its market capitalization, debt, and cash. Used in acquisition pricing to represent the full cost of buying a business.

Total Addressable Market (TAM): The total revenue opportunity available for a product or service if it achieved 100% market share. The expanded definition of women’s health dramatically increases the TAM beyond reproductive care.

Product-Market Fit: The degree to which a product satisfies strong market demand. In healthcare venture, this often means a solution that physicians adopt and continue using because it solves a real clinical or operational problem.

Compound Annual Growth Rate (CAGR): The mean annual growth rate of an investment over a specified period longer than one year. The femtech market’s 15%+ CAGR indicates sustained, accelerating growth.

Series A / Seed: Early-stage venture capital funding rounds. Seed funding supports initial development, while Series A funds companies that have demonstrated early product-market fit and are ready to scale.

Unit Economics: The revenues and costs associated with a single unit of a business model, such as a single patient visit or subscription. Positive unit economics indicate a path to profitability at scale.

Clinical Diligence: The process of evaluating a healthcare company’s clinical validity, workflow integration, and adoption potential through the lens of practicing physicians. Distinct from financial due diligence, which focuses on revenue, margins, and market size.

SOURCES

1. AOA Dx. “Follow the Exits: Why Women’s Health Is a Smart Bet in Healthcare.” Presented at J.P. Morgan Healthcare Conference, January 2026.

2. Femtech Insider. “New Report Finds $100 Billion in Women’s Health Exits Over 25 Years, Challenging ‘Emerging Market’ Narrative.” January 14, 2026.

3. Midi Health. “Midi Health Surpasses $1B Valuation.” Press Release, February 3, 2026.

4. Fierce Healthcare. “Women’s Health Clinic Midi Health Closes $100M Series D as It Aims to Scale a National Healthcare Company.” February 2026.

5. MedCity News. “Digital Health’s Latest Unicorn: Why Investors Are Backing Midi’s Model for Women’s Health.” February 4, 2026.

6. Hologic, Inc. “Hologic to be Acquired by Blackstone and TPG for up to $79 per Share.” Press Release, October 21, 2025.

7. Fierce Biotech. “Hologic to Go Private with $18.3B Acquisition by Blackstone and TPG.” October 22, 2025.

8. Silicon Valley Bank. “2025 Innovation in Women’s Health Report.” April 2025.

9. Silicon Valley Bank / PR Newswire. “Venture Capital Investment in Women’s Health Startups Reaching Record Highs.” April 2, 2025.

10. Astute Analytica / Athletech News. “Global Femtech Market Projected to Reach $267 Billion by 2035.” January 2026.

11. Mayo Clinic Study (2023). Untreated menopause symptoms cost estimate ($25 billion annually in healthcare spending and lost productivity).

12. MedCity News. “MedCity FemFwd: Why Women’s Health Is a Scalable Sector.” February 2026.

13. BioPharma Dive. “Women’s Health Faces Growing Headwinds, Despite Jump in Venture Investment.” May 13, 2025.

14. Accenture & Springboard Report. Women’s health as percentage of total healthcare VC (4% in 2023).

15. HLTH 2025 Panel / SVB Report. Expanded women’s health investment figure ($10.7B in 2024).

16. Gates Foundation. “$2.5 Billion Pledge Over Five Years for Women’s Health Research.” August 2025.

17. McKinsey & Company. “Closing the Women’s Health Gap.” January 2025. (Cited in AOA Dx report: 5% of disease burden exclusive to female biology.)

18. HIT Consultant. “The ‘Unicorn’ of Menopause: Midi Health Hits $1B Valuation with $100M.” February 3, 2026.

The healthcare venture market is sorting. Capital is concentrating on three lanes: AI-native clinical workflows, value-based care infrastructure, and women’s health. February’s funding data confirms the pattern.

For physician capital allocators, this concentration is the signal. The companies raising at scale share one structural advantage: they solved a problem physicians recognized before the market did.

IN TODAY’S ARTICLE:

• Three capital lanes are emerging in healthcare venture: AI-native workflows, value-based specialist infrastructure, and women’s health at scale.

• February’s top rounds collectively exceeded $1.3 billion, with clinical workflow integration as the common denominator across deal sizes from $24 million to $210 million.

• Fund formation continues: Frist Cressey’s oversubscribed $425 million Fund IV brings total AUM* near $1 billion, with strategic LPs* covering over half the U.S. population.

• Vertical integration accelerates as Cigna acquires CarepathRx and physician-owned groups expand into adjacent specialties, rewriting who controls the healthcare value chain.

Glossary at the bottom of today’s article.

The $1.3 Billion Pattern

February moved over $1.3 billion in healthcare capital across two channels. Venture rounds accounted for more than $830 million: Talkiatry ($210 million Series D*), Honest Health ($140 million), Solace ($130 million Series C*), Garner Health ($118 million Series D), Midi Health ($100 million Series D), Chamber Cardio ($60 million Series A*), Alaffia Health ($55 million Series B*), Big Health ($24 million), and others. Fund formation added another $425 million when Frist Cressey Ventures closed an oversubscribed Fund IV.

Scan the list for a pattern. It is there.

Every company raising at this scale either integrates AI into existing clinical workflows, builds infrastructure for value-based care* delivery, or addresses a clinical need that the market historically ignored. The common denominator is AI that works the way physicians already work.

Lane One: AI-Native Workflows

The largest concentration of February capital flowed into companies using AI to reduce clinical friction rather than replace clinical judgment.

Talkiatry raised $210 million in an oversubscribed Series D led by Perceptive Advisors, with participation from Andreessen Horowitz. The company is the largest private employer of psychiatrists in the United States. The model works because psychiatrists practice on Talkiatry’s platform with AI-assisted scheduling, documentation, and care coordination layered underneath. The AI does not diagnose. It removes the administrative drag that prevents psychiatrists from seeing more patients.

Garner Health raised $118 million in a Series D led by Kleiner Perkins with Kaiser Permanente Ventures participating. Garner uses a 60-billion-record claims database to rank physicians by outcomes and match patients accordingly. The AI is the intelligence layer. The physician remains the decision-maker.

Alaffia Health raised $55 million in a Series B to scale AI agents* that automate health plan claims operations. The platform reduces medical cost waste and accelerates clinical review. For physicians, this means fewer claim denials and faster approvals.

The pattern across all three: technology that serves physician autonomy rather than competing with it.

Every company on this list built technology that fits how physicians already work. Recognizing that fit requires clinical experience, not financial modeling. Physicians Capital Fund exists because physicians who invest in healthcare startups bring a diligence advantage that no spreadsheet replicates.

Email: info@46.capital

Lane Two: Value-Based Care Infrastructure

The second capital concentration targeted infrastructure that helps physicians and health systems succeed in value-based payment models*.

Honest Health raised $140 million led by NewSpring Healthcare to expand its technology-enabled care coordination platform for health systems. The company helps organizations execute in risk-based contracts* through quality improvement tools and actionable data. The capital signals growing demand for operational infrastructure, not just clinical tools.

Chamber Cardio raised $60 million in a Series A led by Frist Cressey Ventures with participation from General Catalyst and Optum Ventures. The company builds workflow-native AI for cardiologists, prioritizing high-risk patients, flagging gaps in guideline-directed therapy*, and reducing manual chart review. Cardiovascular disease remains one of the largest drivers of U.S. healthcare spending. Chamber works with over 500 cardiologists across seven states through multiple payer partnerships. The founders include physicians who built the platform around how cardiologists actually practice.

Solace raised $130 million in a Series C to scale its patient advocacy platform connecting Medicare members with healthcare navigators. The model reduces friction between patients and the healthcare system, a workflow problem that physicians encounter daily but rarely have the tools to address at scale.

Each of these companies builds the plumbing that makes value-based care operational for physicians. The capital is flowing to infrastructure, not aspiration.

Lane Three: Women’s Health Reaches Scale

Midi Health raised $100 million in a Series D led by Goodwater Capital, crossing a $1 billion valuation. The company serves more than 25,000 patients per week across 50 states through a network of over 500 clinicians spanning OB/GYN, internal medicine, cardiology, endocrinology, and other specialties.

The unicorn milestone matters, but the market context matters more. An analysis presented at the 2026 J.P. Morgan Healthcare Conference tracked 276 exits of women’s health companies between 2000 and 2024, revealing over $100 billion in cumulative exit value and 27 billion-dollar transactions. The global femtech* market is projected to reach $267 billion by 2035, according to Astute Analytica.

Two million women enter menopause each year in the United States. Untreated symptoms cost an estimated $25 billion annually in medical expenses and lost productivity, according to a 2023 Mayo Clinic study.

Women’s health as a venture category has moved past the “emerging market” label. The capital confirms what physicians in the space have known: the clinical need was always there. The investment was not.

Most market summaries report the funding amounts. This publication reports the pattern underneath them, three times a week, for physicians who deploy capital. No sponsors. No sales pitch.

The Strategic Layer: Consolidation and Vertical Integration

The venture rounds tell one story. The strategic acquisitions tell another.

Cigna’s Evernorth completed its acquisition of CarepathRx, a hospital pharmacy that dispenses prescription drugs to nearly 10% of U.S. hospitals. The deal, discovered through a review of Cigna’s financial filings, reinforces the company’s push to control more of the pharmaceutical supply chain. Cigna acquired Express Scripts for $54 billion in 2018. CarepathRx extends that reach directly into hospital pharmacy operations.

For physicians, the implications are structural. As payers acquire more of the care delivery supply chain, the balance of power shifts. Physicians who understand where capital is consolidating can position accordingly.

Simultaneously, physician-owned practices are expanding laterally. The Cancer & Hematology Centers, Michigan’s largest physician-owned oncology and hematology practice, expanded into urology. Specialty1 Partners formed a joint venture in periodontics. Aria Care Partners acquired Sanford to expand dental and vision services across skilled nursing facilities in the Southeast.

Three forces are simultaneously restructuring the healthcare value chain: venture capital funding, workflow-native startups, strategic acquirers consolidating distribution, and physician groups expanding through specialty acquisitions. Physicians who allocate capital across these lanes are not picking winners in a single category. They are reading the architecture of a market in transition.

Fund Formation: Institutional Conviction Holds

Frist Cressey Ventures closed an oversubscribed $425 million Fund IV, bringing total assets under management to nearly $1 billion. The firm’s Fund I and Fund II rank in the top 5% of all venture capital funds for their respective vintages. Strategic limited partners include The Cigna Group Ventures, MedStar Health, and OhioHealth, organizations that collectively provide healthcare to over half the U.S. population.

The oversubscribed close in the current fundraising environment signals something specific. Institutional investors are not retreating from healthcare venture. They are concentrating their capital in managers who can demonstrate durable access to the care delivery layer. A fund whose LPs cover over 50% of the U.S. population offers portfolio companies something most venture firms cannot: a distribution network embedded in the health system.

For context, global healthcare venture funding reached $14.2 billion in 2025 for U.S. digital health alone, according to Rock Health. AI-enabled companies captured the majority of capital, with the top deals commanding significant premiums. The market is rewarding specificity and clinical integration. Funds that understand the delivery layer have an edge.

What This Means for Physician Capital Allocators

The February data points toward a thesis that physician investors are positioned to evaluate with an advantage.

The market is not rewarding “healthcare AI” as a broad category. It is rewarding AI that integrates into specific clinical workflows, solves problems physicians encounter daily, and operates within existing reimbursement structures. That is a clinical evaluation, not a financial one. Physicians who have spent careers inside these workflows can assess product-market fit* in ways that financial analysts cannot. A network with 68+ years of combined clinical experience across emergency medicine, internal medicine, orthopedics, radiology, and OB/GYN reads these funding rounds differently than a spreadsheet does.

The parallel movements in venture capital, strategic acquisitions, and physician-owned practice expansion indicate that three forces are rebuilding the healthcare value chain. Understanding where each piece fits and where the leverage resides is the capital allocation challenge of this cycle.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital

DISCLOSURE:

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

GLOSSARY

Series A: The first significant round of venture capital financing, typically following seed funding. Series A rounds fund companies that have demonstrated initial product-market fit and are ready to scale.

Series B: A subsequent venture funding round for companies that have moved past the development stage and are scaling operations, expanding market reach, or growing revenue.

Series C: A later-stage venture round for companies with established business models seeking capital for significant expansion, new markets, or acquisition.

Series D: A late-stage venture round, often raised by companies approaching profitability, pursuing major expansion, or preparing for an exit such as an IPO or acquisition.

Value-Based Care: A healthcare delivery model in which physicians and health systems are reimbursed based on patient outcomes rather than the volume of services delivered. Contrasts with traditional fee-for-service models.

Value-Based Payment Models: Reimbursement structures that tie physician compensation to quality metrics and patient outcomes rather than per-procedure billing.

Risk-Based Contracts: Agreements in which physicians or health systems assume financial responsibility for the total cost of care for a defined patient population. Higher quality and lower costs result in shared savings.

Guideline-Directed Therapy: Treatment protocols based on clinical evidence and professional medical guidelines, typically issued by specialty societies. Gaps in guideline-directed therapy represent missed opportunities for optimal patient care.

AI Agents: Software systems that autonomously execute tasks (such as claims processing or clinical review) using artificial intelligence, operating within defined parameters without continuous human oversight.

Unicorn: A privately held startup valued at $1 billion or more.

Femtech: Technology-based products and services focused on women’s health, spanning fertility, pregnancy, menopause, and conditions that disproportionately affect women.

AUM (Assets Under Management): The total market value of investments that a firm manages on behalf of its investors.

LP (Limited Partner): An investor in a venture capital fund who provides capital but does not participate in day-to-day management decisions.

Product-Market Fit: The degree to which a product satisfies strong market demand. In healthcare venture, this often means a solution that physicians adopt and continue using because it solves a real clinical or operational problem.

SOURCES

1. Fierce Healthcare. “Talkiatry Secures $210 Million in Series D Funding.” February 12, 2026.

2. Fierce Healthcare. “Honest Health Raises $140M to Advance Value-Based Care for Health Systems.” February 2026.

3. Fierce Healthcare. “Solace Health Raises $130 Million in Series C Funding.” February 10, 2026.

4. Fierce Healthcare. “Garner Health Rakes In $118 Million in Series D Funding.” February 10, 2026.

5. Fierce Healthcare. “Midi Health Raises $100 Million in Series D, Reaches Unicorn Status.” February 3, 2026.

6. Midi Health. “Midi Health Surpasses $1B Valuation.” Press Release, February 3, 2026.

7. Fierce Healthcare. “Chamber Cardio Raises $60 Million Series A for Value-Based Cardiology.” February 4, 2026.

8. Chamber Cardio. “Chamber Raises $60 Million in Series A Funding to Drive the Future of Cardiology Value-Based Care.” Press Release, February 4, 2026.

9. Fierce Healthcare. “Alaffia Health Secures $55 Million Series B for Agentic AI in Claims.” February 3, 2026.

10. STAT News. “Big Health Raises $24 Million as Investors Bet on Digital Therapeutics.” February 12, 2026.

11. PR Newswire / Frist Cressey Ventures. “Frist Cressey Ventures Announces Oversubscribed $425M Fund IV to Reshape Care Delivery.” February 18, 2026.

12. STAT News. “Cigna Acquires CarepathRx, A Major Pharmacy Used By Hospitals.” February 26, 2026.

13. Fierce Healthcare. “Cigna’s Evernorth Quietly Acquires Hospital Pharmacy CarepathRx.” February 27, 2026.

14. Rock Health. “2025 Year-End Digital Health Funding Overview: A Tale of Two Markets.” January 2026.

15. Astute Analytica / Athletech News. “Global Femtech Market Projected to Reach $267 Billion by 2035.” February 2026.

16. Mayo Clinic Study (2023). Untreated menopause symptoms cost estimate ($25 billion annually).

17. AOA Dx. “Follow the Exits.” Presented at J.P. Morgan Healthcare Conference, January 2026.

18. MedCity News. “5 Notable Health Tech Funding Announcements in February.” March 2, 2026.

19. The Cancer & Hematology Centers. “CHC Expands into Urology Specialty in Michigan.” February 2026.

20. Aria Care Partners. “Aria Care Partners Acquires Sanford for Expansion in Southeast.” February 2026.

21. Specialty1 Partners. “Joint Venture Partnership with Advanced Periodontics Implant Center.” February 2026.

The documentation tool works. The notes are cleaner. The pajama time drops. And yet the prior authorization* still takes 45 minutes. The scheduling system still runs on fax. The billing cycle still leaks revenue.

The scribe solved one problem. The workflow is still broken.

IN TODAY’S ARTICLE:

∙The ambient AI scribe market shows early signs of commoditization, with 100+ funded competitors and EHR incumbents launching native alternatives

∙PitchBook estimates healthcare AI workflow agents represent a $155 billion annual revenue opportunity, driven by more than $300 billion in administrative waste

∙The value chain is migrating from point-solution documentation toward full-stack workflow automation covering scheduling, billing, prior authorization, and revenue cycle management*

∙Physician capital allocators who understand clinical workflow adoption patterns hold a structural advantage in evaluating which platforms will consolidate the category

Glossary at the bottom of today’s article.

The Scribe Market Proved the Model

The ambient AI scribe is the fastest-adopted technology in healthcare history. Adoption rates among physician groups range from 30% to 40% nationally, with leading hospitals reporting utilization as high as 90%.

The category generated $600 million in revenue in 2025, a 2.4x increase year-over-year, and crowned two new unicorns:

Abridge, valued at $5.3 billion after raising $550 million across two rounds, and Ambience Healthcare, which closed a $243 million Series C*.

The business case is straightforward. Physicians spend one hour on documentation for every five hours of patient care.

The AMA reports a 57.8-hour average physician workweek in 2024, with 13 hours dedicated to indirect patient care and 7.3 hours on administrative tasks. Burnout rates, while declining from their 2021 peak, remain high, affecting 43.2% of physicians.

AI scribes addressed a real pain point with measurable results. Physicians adopted the tool quickly because it fit the workflow. That is precisely why the market is now crowding.

The Crowding Problem

More than $4.8 billion has flowed into AI scribe startups since 2019, with $1.6 billion in 2025 alone. PitchBook counts more than 40 funded scribe companies. Other estimates put the number above 100. Capital has outpaced differentiation.

The incumbents are moving. Epic announced its native AI charting tool, Art, developed in partnership with Microsoft. Oracle Health and athenahealth have introduced their own ambient scribes. For health systems already locked into EHR contracts, the switching cost calculus changes when the incumbent bundles documentation into the existing platform at marginal cost.

One venture investor framed the compression clearly: there are more than 100 funded AI scribe companies with largely the same product, all pursuing the same market. The field will not support that number in three to five years.

The scribe proved the model. The question is which companies will use documentation as a wedge into the broader workflow, and which will consolidate parts.

The scribe market proved that physicians adopt AI when it fits the workflow. Recognizing which platforms will own the next layer of that workflow requires clinical pattern recognition, not financial modeling. That is the lens 68 years of combined clinical experience brings to every evaluation.

The $155 Billion Workflow Opportunity

PitchBook published a landmark analyst note in December 2025, estimating that healthcare AI workflow agents represent a $155 billion annual revenue opportunity.

The thesis: ambient scribes are evolving into full-stack workflow automation platforms, and the addressable market* extends far beyond documentation.

The numbers frame the scale. U.S. healthcare administrative spending runs approximately $1 trillion annually. Wasteful administrative spending accounts for $285 billion to $570 billion per year, according to Health Affairs. Medical documentation and back-office revenue cycle management alone comprise roughly $38 billion, or nearly 60% of all healthcare IT spending.

The larger opportunity sits in administrative work that never carried IT budgets. Prior authorization, patient engagement, and front-office revenue cycle management have historically been people-intensive workflows funded through service budgets. Within the $740 billion in total administrative spend, software accounts for a fraction.

Prior authorization processing alone costs $40 to $50 per submission for private payers. AI has the potential to convert services dollars into software dollars at scale.

Venture capital is responding. Startups building healthcare AI agents raised $3.4 billion through Q3 2025, nearly doubling 2024 levels.

The leading companies are expanding beyond documentation into coding, billing, prior authorization, and clinical decision support.

Where the Value Migrates

The scribe companies that survive will be the ones that expanded early. Abridge is partnering with Highmark Health to deploy AI for real-time prior authorization.

Ambience released an AI copilot* that works within Epic to surface real-time clinical information beyond documentation.

Innovaccer, Smarter Technologies, and OpenEvidence are building across the value chain.

The taxonomy identifies three categories of healthcare AI agents: physician-facing (clinical workflow), payer-facing (utilization management, payment integrity), and hybrid “payvider” agents that bridge both sides.

The companies capturing durable value will sit at the intersection of clinical workflow and financial workflow, because that is where the administrative waste concentrates.

The evaluation framework shifts. The question is no longer “does this tool save documentation time?” The question is: does this platform own enough of the workflow to become essential infrastructure?

That distinction is clinical. It requires understanding how physicians actually move through a workday, where friction points compound, and which integrations reduce total workflow burden rather than shifting it between systems.

Traditional venture diligence does not surface these answers. Clinical diligence* does.

The ambient scribe market attracted $4.8 billion before most venture firms understood why physicians adopted it.

The workflow agent opportunity is multiples larger. The funds with physician networks will evaluate it based on workflow reality, not TAM* slides.

What Physicians See That Models Miss

The difference between a documentation tool and a workflow platform is not visible in a pitch deck. It is visible in a physician’s day.

A physician evaluating an AI scribe asks one question: does this reduce my after-hours documentation? A physician evaluating a workflow platform asks a different set. Does this reduce the 45 minutes I spend on prior authorization for a single patient? Does this catch the billing code that revenue cycle missed? Does the scheduling integration reduce my no-show rate? Does the platform connect to my EHR without creating a new login?

These are operational questions. They require operational knowledge. The investors who can answer them before writing a check hold a structural advantage in a market approaching rapid consolidation.

Healthcare AI spending nearly tripled to $1.4 billion in 2025. Eight healthcare AI unicorns emerged in a single year. Digital health funding in H1 2025 reached $6.4 billion, with 62% flowing to AI-enabled startups. The capital is moving. The question is whether it is moving toward the right platforms.

The scribe was the opening chapter. The workflow is the thesis.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Pre-Seed - Series A healthcare companies focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com

Email: info@46.capital

GLOSSARY

Prior Authorization: The process by which a health insurer requires a physician to obtain approval before performing a procedure, prescribing a medication, or referring a patient for specialty care. Widely cited as one of the most burdensome administrative tasks in clinical practice.

Revenue Cycle Management (RCM): The financial process that healthcare organizations use to track patient care episodes from registration and appointment scheduling through final payment. Includes coding, billing, claims processing, and collections.

AI Copilot: A software tool that works alongside a physician in real time, providing clinical information, coding suggestions, or documentation support within the existing workflow.

Clinical Diligence: The process of evaluating a healthcare investment through the lens of clinical workflow, adoption feasibility, and physician utility, as distinct from traditional financial due diligence.

Total Addressable Market (TAM): The total revenue opportunity available for a product or service if it achieved 100% market share. Used in venture capital to size the potential scale of an investment.

Series C: A later-stage venture capital funding round, typically used to scale a company that has already demonstrated product-market fit and significant revenue growth.

SOURCES

1. PitchBook. Q4 2025 Analyst Note: Healthcare Services AI Agents: A $155 Billion Opportunity. PitchBook, December 2025.

2. PitchBook. Q4 2025 Analyst Note: Healthtech AI Scribes. PitchBook, 2025.

3. Menlo Ventures. 2025: The State of AI in Healthcare. Menlo Ventures, November 2025.

4. Rock Health. H1 2025 Digital Health Funding Report. Rock Health, July 2025.

5. American Medical Association. 2024 National Physician Comparison Report (AMA Organizational Biopsy). AMA, August 2025.

6. Health Affairs. The Role of Administrative Waste in Excess U.S. Health Spending. Health Affairs, 2022.

7. McKinsey & Company / Harvard. Administrative Spending and Healthcare Waste Estimates. Referenced in NEJM Catalyst, 2025.

8. Healthcare Dive. Top Healthcare AI Trends in 2026. Healthcare Dive, January 2026.

9. Fierce Healthcare. Healthcare AI Rakes in Nearly $4B in VC Funding. Fierce Healthcare, July 2025.

10. Crunchbase. Sector Snapshot: Funding to AI-Related Healthcare Startups. Crunchbase, November 2025.

The average among peer nations was roughly half that.
Yet American life expectancy still lags, trailing Germany’s by 3-4 years.
Preventable deaths remain high.
The system remains tilted toward late-stage intervention.

The dollars are already in the system.
The question is: why does so little of that spending produce value?

IN TODAY’S ARTICLE:

• The anatomy of $5.6 trillion: hospital care, physician services, administration, and drugs

• Three categories of inefficiency that merit capital allocation attention

• The outpatient shift is already underway, and it captures the economics.

• How clinical diligence reveals adoption barriers invisible to financial analysis

Glossary at the bottom of today’s article.

The Anatomy of $5.6 Trillion

Understanding where excess spending concentrates is a prerequisite to understanding where capital can be deployed effectively.

U.S. healthcare expenditure reached $5.3 trillion in 2024, representing 18% of GDP*, compared with approximately 11-12% in peer nations. CMS projects spending will reach $5.6 trillion in 2025, up 7.1%. But aggregate figures obscure the structural composition of that spending.

Hospital care accounts for 31% of total expenditure, reaching $1.6 trillion in 2024 and projected to hit $1.8 trillion in 2025. Physician and clinical services represent 21%, totaling $1.1 trillion. Prescription drugs consume 9%, at $467 billion. Administrative costs absorb an estimated 15-30% of total healthcare spending, with the most comprehensive study finding that they accounted for 34.2% of national health expenditures in 2017.

The Commonwealth Fund identified administrative complexity as the largest single component of excess U.S. healthcare spending relative to peer nations.

The distribution matters because it reveals which segments of the system have resisted efficiency gains and which remain vulnerable to disruption.

Hospital spending has remained stubbornly concentrated despite decades of policy interventions aimed at shifting care to lower-acuity settings. The reasons are structural: fee-for-service* reimbursement incentivizes volume over value, hospital systems have consolidated market power that insulates them from competitive pressure, and the capital requirements for hospital infrastructure create barriers to entry that protect incumbents.

Administrative spending presents a different profile. The complexity is largely artificial: a consequence of fragmented payers, misaligned incentives, and legacy technology infrastructure. Unlike hospital consolidation, administrative burden is not protected by structural moats. It persists because the stakeholders who bear the cost (physicians and patients) are not the stakeholders who control the systems (payers and intermediaries).

These distinctions matter for capital allocation. Attacking hospital economics directly requires either regulatory change or sufficient scale to negotiate against consolidated systems. Attacking administrative waste requires technology and workflow integration. Different risk profiles. Different return characteristics.

The difference between a good healthcare investment and a great one is usually clinical. Most VCs learn this after the hold period extends. Physicians in our network learn it before they write the check.

Inefficiencies as Investment Thesis

Waste shows where the system breaks. It also shows where new models can take hold.

The years 2023 and 2024 marked the strongest consecutive years of healthcare spending growth since 1991-1992. Spending rose 7.4% in 2023 and 7.2% in 2024. CMS attributes this acceleration to increased utilization and service intensity, not to price growth. The demand for medical care rebounded from pandemic-related suppression and continued to climb.

That persistence points to structural inefficiency that cannot be resolved through incremental policy adjustment.

Three categories of inefficiency merit particular attention for capital allocation:

1. Care Delivery Fragmentation

The fragmentation of care delivery across settings, specialties, and systems creates redundancy and gaps. A patient with multiple chronic conditions may see six or more physicians, none of whom have complete visibility into the others’ care plans—the result: duplicated tests, conflicting prescriptions, and missed handoffs.

Technologies that create continuity across fragmented care settings address a structural inefficiency. Remote patient monitoring* (RPM) is one example: continuous data collection provides visibility that episodic visits cannot. For chronic conditions like diabetes and congestive heart failure, RPM gives physicians real-time visibility, reduces unnecessary admissions, and enables earlier, lower-cost intervention.

2. Diagnostic Delays

Late diagnosis remains one of the most expensive failures in healthcare. A condition identified at Stage IV costs the system and the patient exponentially more than the same condition identified at Stage I. Yet diagnostic infrastructure remains concentrated in acute settings, accessible primarily when symptoms have already progressed.

Point-of-care diagnostics, AI-assisted imaging interpretation, and risk stratification tools all help address diagnostic delay. The investment thesis is not the technology itself but the economic logic: earlier identification enables earlier intervention at lower total cost.

3. Administrative Complexity

Prior authorization alone consumes an estimated 13 hours per physician per week, according to AMA survey data. Revenue cycle management absorbs 3-5% of net patient revenue. Credentialing delays cost physician practices $7,500 to $10,000 per physician per month in unrealized revenue.

These are not clinical problems. They are workflow problems. And workflow problems are tractable to software in ways that clinical problems are not.

The Outpatient Shift

One structural trend is already underway and accelerating: the migration of care from inpatient to outpatient settings.

Ambulatory surgery centers have grown approximately 15% over the past decade. Outpatient procedures often cost 40% less than their inpatient equivalents. Payers have strong incentives to shift volume; health systems have strong incentives to retain it.

The tension creates opportunity. Companies that facilitate the shift, whether through technology, logistics, or new care models, are positioned on the right side of the cost curve. Companies that depend on inpatient volume face structural headwinds regardless of their execution.

Physicians understand this shift because they are living it. The movement of procedures from hospital operating rooms to ambulatory surgery centers is not theoretical; it is happening in their practices. That ground-level visibility is clinical diligence* in action.

We do not chase deals. We do not pitch. We have conversations with physicians who allocate capital and founders who understand clinical workflow. If that describes you, the door is open.

Clinical Diligence as Competitive Advantage

The question for capital allocators is not whether healthcare inefficiency exists. It does. The question is which inefficiencies are addressable through private investment and which require structural or regulatory change that private capital cannot catalyze.

Answering that question requires clinical insight.

A technology that appears promising in a pitch deck may flounder when it comes to integrating with workflows. A market that appears large in TAM* analysis may be inaccessible due to reimbursement constraints. A solution that solves a real problem may fail adoption because it adds friction to already-burdened clinicians.

Physicians see these barriers. They live them. That visibility is what separates a good healthcare investment from a great one.

47% of digital health startups fail within 3 years. The common denominator is not funding. It is not technology. It is clinical workflow integration. Most founders build for the pitch deck. They optimize for demo day, not day-to-day. The result: tools that look good in a demo but never get adopted.

Physicians see this immediately. They know the difference between a tool that fits the workflow and one that interrupts it.

PhyCap’s network includes physicians across emergency medicine, internal medicine, orthopedics, spine surgery, radiology, OB/GYN, and other specialties. When we evaluate a company building in any of these domains, we can ask the physicians who will actually use the technology whether they would adopt it. That is clinical diligence.

The overspending map shows where the dollars are. Clinical diligence shows which dollars are accessible.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Seed and Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital

LinkedIn: PhyCapFund LinkedIn
X: Connect with us on X

GLOSSARY

GDP (Gross Domestic Product): The total monetary value of all goods and services produced within a country’s borders in a specific time period. Healthcare spending as a percentage of GDP indicates how much of the economy is devoted to health services.

Fee-for-Service: A payment model in which physicians and healthcare facilities are paid for each service they provide (each test, procedure, or visit) rather than for overall patient outcomes. This model incentivizes volume over value.

Remote Patient Monitoring (RPM): Technology that enables healthcare providers to monitor patients outside of conventional clinical settings using digital devices that collect and transmit health data. Examples include connected blood pressure monitors, glucose monitors, and heart rate sensors.

Clinical Diligence: The process of evaluating healthcare investments through the lens of clinical workflow, adoption barriers, and physician perspective, rather than purely financial or market analysis.

TAM (Total Addressable Market): The total revenue opportunity available for a product or service if 100% market share were achieved. In healthcare, TAM figures can be misleading because reimbursement constraints, regulatory requirements, and adoption barriers often make large portions of the theoretical market inaccessible.

SOURCES

1. Centers for Medicare & Medicaid Services. “National Health Expenditure Data: Historical.” CMS.gov, June 2025.

2. Centers for Medicare & Medicaid Services. “NHE Fact Sheet.” CMS.gov, 2025.

3. Organisation for Economic Co-operation and Development. “Health Spending.” OECD Data, 2024.

4. Himmelstein, David U., et al. “Health Care Administrative Costs in the United States and Canada, 2017.” Annals of Internal Medicine, 2020.

5. The Commonwealth Fund. “U.S. Health Care from a Global Perspective, 2022.” Commonwealth Fund Report, 2023.

6. American Medical Association. “2022 AMA Prior Authorization Physician Survey.” AMA, 2022.

7. Medical Group Management Association. “Annual Regulatory Burden Report.” MGMA, 2023.

8. Rock Health. “H1 2024 Digital Health Funding Report.” Rock Health, 2024.

DISCLOSURE: This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

Runtime: 17 minutes Format: Point-Counterpoint Debate

The Central Question

Should venture capital be evaluated solely on financial returns (IRR, multiples, cash-on-cash), or is there a “hidden yield” that compounds independently and creates equal or greater value for physician investors?

The Two Positions

Position A: The Synthesis View

Financial returns are the floor, not the ceiling.

The argument: For physicians, venture capital delivers value along two tracks simultaneously. Yes, the fund must be financially viable. However, the non-financial returns, information asymmetry, network density, and clinical credibility compound independently and create strategic advantages that traditional asset classes cannot replicate.

Key claims:

• Venture participation creates 24-36 month forward visibility into healthcare innovation

• Physicians gain “sector intelligence” by seeing tools, diagnostics, and workflow optimizations before widespread adoption

• Network effects produce professional collaboration, referral relationships, and knowledge exchange that operate independently of fund returns

• The illiquidity of VC actually aligns with physician career trajectories (capital at 40 returns in the 50s)

• Clinical diligence transforms physicians from passive capital to active value creators

The bottom line: “The question is not whether hidden benefits justify the risk on their own. The question is whether a portfolio that ignores them is fully optimized.”

Position B: The Fiduciary View

You can’t pay a mortgage with insight.

The argument: Venture capital is a high-risk, illiquid asset class. The fiduciary obligation to generate returns isn’t just a component — it’s the whole game. Introducing concepts such as “professional development” or “strategic foresight” into the investment thesis muddies the waters and risks conflating professional curiosity with serious investment strategy.

Key claims:

• If a fund returns 3x, learning is irrelevant; if it returns 1x, sector intelligence doesn’t compensate for underperforming the S&P 500

• “Hidden yield” is often marketing language for underperformance

• Physicians are already busy professionals; adding deal flow evaluation requires justification in hard numbers

• Network effects sound good but rely on serendipity — “a great network with a bad portfolio is just a support group for losing money.”

• Opportunity cost of 10-year capital lockup is significant in high-interest-rate environments

The bottom line: “Pattern recognition and conversations are great, but they must eventually translate to hard financial exits. The fiduciary obligation cannot be waived for the sake of feeling involved in innovation.”

Key Debate Moments

On Information Asymmetry

Pro: “If you see five companies all trying to solve billing efficiency using AI, you know that problem is about to be solved. You stop hiring manual billers. That’s an immediate operational decision derived from VC exposure.”

Con: “That’s a very specific scenario. What about the employed physician? For them, this intelligence is academic. It’s cocktail party conversation.”

On Network Value

Pro: “The Journal of Finance has published findings showing that network-driven investors secure better terms and higher returns. Information flows through relationships.”

Con: “If I want referrals, I can take a colleague out to dinner for a lot less than a capital commitment.”

On Clinical Diligence

Pro: “The best investment committees include people who have actually used the stethoscope. When physicians apply their clinical edge, better diligence leads to better portfolio performance. It’s a flywheel.”

Con: “I won’t argue that physicians make better diligence partners for the fund. But why should the physician care about helping the fund manager do their job?”

On Illiquidity

Pro: “Physicians think in decades, not quarters. A surgeon in their 40s has 20+ years of practice left. The illiquidity prevents emotional selling. It’s a feature, not a bug.”

Con: “In a high-interest-rate environment, locking up capital for 10 years carries a heavy penalty if the returns aren’t stellar. If the sector intelligence was wrong, you’re stuck.”

The Synthesis

Both debaters agree on one thing: Financial returns remain the fiduciary obligation. The hidden yield does not replace the need for fund performance.

The disagreement is whether ignoring the non-financial benefits constitutes a missed optimization opportunity, or whether emphasizing them distracts from the only metric that ultimately matters.

The question left for the listener:

Are you content with the spreadsheet view, or do you want to leverage your clinical edge?

Why This Matters for PhyCap LPs

This debate captures the core tension physician investors face when evaluating venture capital:

1. You already have the clinical expertise. The question is whether to deploy it passively (allowing others to capture the value) or actively (using it to inform your own capital allocation).

2. The timing works. Physician career trajectories align more closely with VC hold periods than almost any other investor profile.

3. The network is curated. PhyCap’s physician network spans emergency medicine, internal medicine, orthopedics, spine surgery, radiology, OB/GYN, and more. This isn’t LinkedIn. It’s relationship density with shared context.

4. Clinical diligence is the moat. The ability to distinguish between a tool that fits the workflow and one that doesn’t is learned through clinical practice. Most VCs don’t have it. You do.

DISCLAIMER:

This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

It compounds in conversations. In pattern recognition. In the quiet accumulation of insight that separates sophisticated allocators from passive capital.

Financial returns dominate the venture capital conversation for obvious reasons. They are measurable, comparable, and ultimately the fiduciary obligation that underlies every allocation decision.

And when accredited investors*, particularly physicians, evaluate a venture commitment solely through the lens of IRR* and multiples*, they overlook an entire category of strategic value that compounds independently of fund performance. These hidden returns do not replace the importance of financial outcomes. They augment them.

IN TODAY’S ARTICLE:

• Why venture capital exposure creates information asymmetry* that traditional asset classes cannot replicate

• How network effects* in healthcare venture produce professional advantages that extend well beyond the portfolio

• The compounding value of entrepreneurial pattern recognition for physician investors

• Why long-duration commitment structures align uniquely well with physician career trajectories

Terms marked with an asterisk (*) are defined in the glossary at the end of this article.

The Information Asymmetry Advantage

Physicians operate in one of the most rapidly evolving sectors of the global economy. New care delivery models, regulatory shifts, reimbursement changes, and technological innovation continuously reshape the landscape.

Yet most physicians experience these changes reactively. They learn about new technologies when they are added to their EMR. They discover care delivery innovations when their health system adopts them.

Venture capital inverts this dynamic.

By participating in early-stage healthcare investing, physicians gain forward visibility into the innovation pipeline. They see what is being built before it reaches clinical adoption. They understand where capital is flowing and why. They develop what professional investors call “sector intelligence*” through direct exposure to companies that are solving tomorrow’s problems.

This is not abstract value. A physician who understands emerging remote patient monitoring* platforms two years before widespread adoption makes better technology decisions for their practice.

A specialist who recognizes the trajectory of AI-assisted diagnostics can position their career accordingly. A healthcare executive who sees where venture dollars concentrate gains strategic foresight that informs operational planning.

According to PitchBook data, venture-backed technology companies accounted for over 60% of total IPO proceeds in 2023. The implications extend beyond financial markets. These companies represent the commercial vanguard of innovation. Proximity to them creates information advantages that compound over time.

Network Effects That Extend Beyond Capital

Venture capital is fundamentally a network-driven asset class. Deal flow*, diligence quality, and portfolio company support all depend on relationship density. For physician investors, this network dimension creates professional value that operates independently of fund returns.

Consider the composition of a typical healthcare-focused venture fund’s LP* base. It includes institutional allocators, family offices, successful entrepreneurs, and increasingly, physician investors who bring clinical expertise to the diligence process. Each connection represents potential for professional collaboration, referral relationships, and knowledge exchange.

This is networking as it was intended. It is access to a curated community of individuals who share specific interests: healthcare innovation, capital allocation, and long-term wealth creation. The conversations that emerge from these connections tend to be substantive because the context demands it.

Research published in the Journal of Finance demonstrates that network-driven investors in venture funds secure better deal terms and higher returns due to early access to high-quality investments. But the mechanism underlying this finding reveals something important about network value. Information flows through relationships. Investors embedded in dense networks encounter opportunities earlier and evaluate them with more context.

For physicians, who often operate in professional silos defined by specialty and geography, venture participation expands the aperture. It creates connection points with founders building the next generation of healthcare companies, with executives scaling innovative models, and with fellow investors who bring complementary perspectives.

The spreadsheet sees a $5 trillion market.
The physician sees exactly which $200 billion is leaking through the cracks they walk past every day. That visibility is not sentiment. It is edge.
PhyCap exists to deploy it.

The Satisfaction of Proximate Impact

Physicians chose medicine to solve problems. The daily work of clinical care delivers this satisfaction in immediate, tangible form. A diagnosis clarified. A treatment that restores function. A life extended.

Venture capital offers a different but related form of impact.

Early-stage healthcare companies face a credibility gap. They have conviction. Often technology. Sometimes, early clinical evidence. What they frequently lack: validation from the professionals who will ultimately adopt their solutions.

When physicians invest, they provide more than capital. They signal clinical relevance. The implicit endorsement of a practitioner who commits personal resources to a company’s success carries weight with other investors, potential customers, and the founders themselves.

The best investment committees include people who have actually used a stethoscope. Clinical judgment cannot be modeled. The ability to distinguish between a workflow tool that will be adopted and one that will be ignored is developed through repeated use in clinical environments. Physicians bring that judgment to the table.

For physician investors who engage beyond passive allocation, participating in clinical advisory boards, contributing to diligence calls, and providing feedback on product development, the satisfaction of proximate impact becomes tangible. They see their expertise translated into company decisions. They watch portfolio companies iterate based on clinical input. They experience the connection between insight and outcome that drew them to medicine in the first place.

Long-Duration Alignment

The illiquidity of venture capital is frequently cited as a disadvantage. For physicians, it may be the opposite.

Physician careers operate on long time horizons. A surgeon in their early forties may practice for another twenty-five years. A primary care physician building a practice thinks in decades, not quarters. The professional planning cycle for physicians naturally accommodates long-duration commitments.

This alignment has practical implications. Physicians can commit capital to venture funds without the liquidity anxiety that constrains investors with shorter planning horizons. They can absorb the J-curve* without emotional distress because their financial architecture does not depend on near-term distributions.

The venture capital hold period, typically 8 to 12 years, maps comfortably onto physician career trajectories. Capital committed at age forty returns during the peak earning years of the late forties and fifties. Capital committed at fifty returns during the transition to reduced clinical hours or retirement. The timing works.

This structural alignment is underappreciated. Most venture capital literature assumes investors require liquidity within five years. Physicians do not. Their income stability and career duration create a natural fit with an asset class that rewards patience.

The Co-Investment Opportunity

As physician investors develop track records and relationships with fund managers, they may gain access to co-investment opportunities. Co-investment allows LPs to invest directly in specific portfolio companies alongside the main fund, often with reduced fees and increased exposure.

Co-investment is not for every investor. It requires additional diligence, introduces concentration risk*, and demands more active engagement. But for physician investors who identify companies operating in their clinical domain, co-investment offers a path to deeper involvement.

A cardiologist who encounters a cardiac monitoring platform through their fund portfolio may have unique insight into the company’s clinical value proposition. A radiologist who sees an AI-assisted imaging company in their fund’s holdings may be positioned to evaluate the technology more rigorously than generalist investors. Co-investment transforms this knowledge advantage into increased exposure.

The opportunity itself signals the collaborative nature of modern venture investing. General partners* benefit from LP expertise. LPs benefit from access to opportunities screened by professional investors. The alignment creates value for both parties.

We built PhyCap around a simple observation: physicians bring something to healthcare investing that financial models cannot capture. Clinical judgment. Pattern recognition honed over thousands of patient encounters. The ability to distinguish innovation from iteration. If you have spent years developing that expertise, it seems worth exploring how it might compound in a different context.

The Compounding Portfolio Effect

The benefits described above do not operate in isolation. They compound.

The physician who gains early visibility into care-delivery innovations makes better practice decisions. Better practice decisions improve professional outcomes. Improved professional outcomes create capacity for increased investment. Increased investment expands network access. Expanded networks surface better opportunities. Better opportunities improve portfolio performance. Improved portfolio performance enables larger future commitments.

This is the flywheel that sophisticated healthcare investors understand. Financial returns matter. They matter enormously. But they represent one component of a value proposition that extends across professional development, network building, and strategic positioning.

The question for physician investors is not whether these hidden benefits justify exposure to venture capital. The question is whether a capital allocation strategy that ignores them is fully optimized.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Seed and Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.

Website: PhyCapFund.com
Email: info@46.capital

GLOSSARY

Accredited Investor: An individual or entity meeting SEC criteria for investing in private securities, including income thresholds ($200K individual/$300K joint) or net worth requirements ($1M excluding primary residence).

Co-Investment: The opportunity for limited partners to invest directly in specific portfolio companies alongside the main fund, often at reduced fees.

Concentration Risk: The potential for amplified losses when a portfolio is heavily weighted toward a single investment or sector.

Deal Flow: The rate and quality of investment opportunities presented to a fund or investor.

General Partners (GPs): The fund managers responsible for investment decisions, portfolio management, and fund operations.

Information Asymmetry: A situation where one party in a transaction possesses more or better information than another, creating potential advantage.

IRR (Internal Rate of Return): A metric used to estimate the profitability of potential investments, accounting for the time value of money.

J-Curve: The typical performance pattern of a venture fund, showing negative returns in early years followed by positive returns as portfolio companies mature and exit.

Limited Partners (LPs): Investors who commit capital to a fund but do not participate in day-to-day management decisions.

Multiples: A measure of investment return expressed as a multiple of invested capital (e.g., 3x means $3 returned for every $1 invested).

Network Effects: The phenomenon where a product or service gains additional value as more people use it or participate in it.

Remote Patient Monitoring (RPM): Technology enabling the collection of patient health data outside traditional clinical settings.

Sector Intelligence: Deep, specialized knowledge about trends, dynamics, and opportunities within a specific industry or market segment.

SOURCES

1. PitchBook. (2024). “2023 Annual Venture Capital Report.” PitchBook Data, Inc.

2. Journal of Finance. (2019). “Network Effects and Investment Performance in Venture Capital.”

3. Cambridge Associates. (2024). “U.S. Venture Capital Index and Selected Benchmark Statistics.”

4. PitchBook. (2024). “Health Tech Venture Funding: Five-Year Trend Analysis.”

DISCLAIMER

DISCLOSURE: This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

Venture capital is not a mystery. It is a discipline with learnable mechanics, predictable rhythms, and identifiable risks. The question is not whether physicians can access this asset class. They already qualify. The question is whether they will engage it with the same rigor they apply to clinical practice.

IN TODAY’S ARTICLE:

• Why physician income profiles naturally satisfy accredited investor* requirements

• The structural realities of venture capital: illiquidity*, the J-curve*, and time horizons

• How to evaluate a fund’s thesis, sector focus, and alignment with your own expertise

• The difference between passive allocation and informed participation

Terms marked with an asterisk (*) are defined in the glossary at the end of this article.

The Accreditation Threshold You Already Clear

The Securities and Exchange Commission defines an accredited investor* as an individual with annual income exceeding $200,000 ($300,000 for married couples) for the past two years, or a net worth above $1 million excluding primary residence.

According to Medscape’s 2024 Physician Compensation Report, the average physician salary in the United States is $363,000. Specialists in procedural fields routinely exceed $500,000. This means most attending physicians qualify for accredited investor status within their first few years of practice.

This is not a technicality. It is access.

Accreditation opens the door to private market investments that are unavailable to retail investors: private equity*, venture capital*, hedge funds, and direct startup investments. These asset classes have historically outperformed public markets over long time horizons, though they carry distinct risk profiles and liquidity constraints.

The barrier for most physicians is not qualification. It is orientation. Medical training emphasizes clinical mastery, not capital deployment. The result: high earners with limited exposure to the mechanics of private investing.

What Venture Capital Actually Is

Venture capital is a subset of private equity focused on early-stage companies with high growth potential. Investors provide capital in exchange for equity*, typically through a fund structure managed by a general partner (GP). The GP identifies opportunities, conducts due diligence, negotiates terms, and manages the portfolio. Investors in the fund are limited partners (LPs)*, who commit capital but do not control day-to-day decisions.

This structure exists for a reason. Early-stage investing requires specialized expertise, deal flow access, and active management. Individual investors rarely have the time, network, or operational bandwidth to source and manage a portfolio of startups directly. Fund structures aggregate capital and distribute risk across multiple companies.

The tradeoff is illiquidity*. Once you commit capital to a venture fund, that money is typically locked for 8 to 12 years. There is no secondary market. There are no quarterly redemptions. You are in until the fund exits its positions, usually through acquisitions or initial public offerings (IPOs).

For physicians accustomed to liquid investments like index funds or publicly traded equities, this can feel constraining. But illiquidity is not a bug. It is the mechanism that allows venture capital to capture returns unavailable in public markets. Companies need time to scale. Investors who demand quarterly liquidity cannot participate in that growth curve.

The J-Curve Is Not a Warning. It Is a Pattern.

New venture investors often experience anxiety when their fund reports negative returns in the first two to three years. This is expected. It is called the J-curve*.

In the early years of a fund, capital is deployed, but exits have not yet occurred. Management fees are charged against committed capital. Valuations may be written down before they are written up. The math produces negative returns on paper.

Then the curve inflects. Portfolio companies mature. Exits begin. Returns compound. By year six or seven, well-performing funds typically show meaningful positive returns. By year ten, the full picture emerges.

Physicians should find this pattern familiar. Early-stage clinical data often looks discouraging before the therapeutic effect becomes clear. Initial imaging findings rarely tell the whole story. The discipline required to interpret venture fund performance mirrors the discipline required to interpret longitudinal clinical outcomes.

The investors who panic at the bottom of the J-curve are the investors who should not have been in the asset class. The investors who understand the pattern allocate accordingly and wait.

The difference between a good healthcare investment and a great one is usually clinical. Most VCs learn this after the hold period extends. Physicians in our network learn it before they write the check.

How to Evaluate a Fund

Not all venture funds are created equal. The dispersion between top-quartile and bottom-quartile funds is wider in venture capital than in any other asset class. Fund selection matters more here than anywhere else.

When evaluating a fund, consider:

Thesis clarity. What is the fund investing in, and why? A fund focused on “healthcare innovation” is not a thesis. A fund focused on “clinical workflow optimization tools that reduce administrative burden for specialty practices” is a thesis. Specificity indicates rigor.

Sector expertise. Does the GP have operating experience in the sector they are investing in? In healthcare, this question is critical. The difference between a compelling pitch deck and a clinically viable product is often invisible to generalist investors. Domain expertise closes that gap.

Track record. Has the GP deployed capital before? What were the outcomes? First-time funds can outperform, but they carry additional risk. Experienced GPs bring pattern recognition that compounds over multiple fund cycles.

Alignment. How does the GP get paid? Carried interest* structures that reward long-term performance align GP incentives with LP outcomes. Structures that front-load management fees do not.

Network. Does the fund have relationships that can help portfolio companies succeed? In healthcare, this means clinical advisors, regulatory expertise, and connections to health systems and payers. Capital alone is rarely sufficient.

The Physician Advantage in Healthcare Venture

Physicians bring something to healthcare venture capital that no financial model can replicate: clinical judgment.

They know which workflows actually frustrate practitioners. They understand which regulatory pathways are navigable and which are quagmires. They can distinguish between technology that solves a real problem and technology that solves a theoretical one.

This expertise has value at every stage of the investment process. In sourcing, physician networks surface opportunities that never reach generalist investors. In diligence, clinical insight identifies risks and opportunities that spreadsheets miss. In portfolio support, physician advisors help companies navigate the adoption curve.

The best healthcare venture funds recognize this. They do not merely accept physician capital. They seek physician participation in diligence, advisory roles, and network development.

For physicians considering venture allocation, the question is not just “which fund should I invest in?” It is “which fund will leverage my expertise rather than just my capital?”

Most investors see healthcare as a sector.
Physicians see it as a system.
The vantage point matters.
If you have spent years navigating that system,
PhyCap is where that experience becomes deployable capital.

Position Sizing and Portfolio Construction

Venture capital is not a replacement for a diversified portfolio. It is a compliment.

Most institutional allocators target 5% to 15% of their portfolio in venture capital, depending on risk tolerance and liquidity needs. Individual investors should calibrate accordingly.

The preferred commitment range for physicians engaging with PhyCap is $50,000 to $250,000. This allows meaningful participation without overconcentration. It also permits diversification across multiple funds over time, thereby reducing vintage-year risk*.

The discipline is straightforward: commit only capital you can afford to lock for a decade. If you need the money for a house, a practice acquisition, or education expenses within the next ten years, it does not belong in venture.

BONUS PODCAST:

Go with us on a deep dive into “The Physician’s Entry Point to Venture Capital”.

WORK WITH PHYCAP FUND

Physicians Capital Fund invests $150K-$500K in Seed and Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health

Website: PhyCapFund.com
Email: info@46capital.com
LinkedIn: LinkedIn
X: X (formerly twitter)

GLOSSARY

Accredited Investor: An individual meeting SEC income or net worth thresholds, qualifying them to invest in private securities offerings.

Carried Interest: The share of fund profits (typically 20%) paid to the general partner after returning committed capital and preferred returns to limited partners.

Due Diligence: The investigative process of evaluating an investment opportunity, including financial, operational, legal, and market analysis.

Equity: Ownership stake in a company, typically represented by shares.

General Partner (GP): The fund manager responsible for sourcing deals, managing portfolio companies, and making investment decisions.

Illiquidity: The inability to easily convert an investment into cash without significant loss of value or extended time.

J-Curve: The typical performance pattern of a venture fund, showing negative returns in early years followed by positive returns as portfolio companies mature and exit.

Limited Partner (LP): An investor in a venture fund who commits capital but does not participate in day-to-day management.

Private Equity: An asset class consisting of investments in private companies not traded on public exchanges.

Venture Capital: A subset of private equity focused on early-stage, high-growth companies.

Vintage Year Risk: The risk that a fund’s performance is influenced by the economic conditions at the time of its initial investments.

SOURCES

1. U.S. Securities and Exchange Commission. “Accredited Investor Definition.” SEC.gov.

2. Medscape. “Physician Compensation Report 2024.” Medscape.com.

3. Cambridge Associates. “U.S. Venture Capital Index and Selected Benchmark Statistics.” 2024.

4. PitchBook. “Healthcare Venture Capital Performance Analysis.” 2024.